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1. Zusammenfassung 
Onkogenes KRas wird mit einer Vielzahl von Krebserkrankungen wie Bauch-
speicheldrüsen-, Dickdarm- und Lungenkarzinomen assoziiert, die mit einer 
schlechten Prognose und Überlebenschance für den Patienten einhergehen. 
Durch onkogene Mutationen wird Ras in einem dauerhaft aktiven Zustand ge-
halten und nachgeschaltete Signalkaskaden werden so permanent aktiviert. Die 
Folgen sind unkontrolliertes Wachstum und Überleben entarteter Zellen. Des-
halb stellen alle Ras-Proteine interessante Angriffspunkte für zielgerichtete 
Krebs-Therapien dar. Trotz bekannter Struktur und Funktionen ist Ras bis heute 
ein „undruggable“ Protein, bei dem eine zielgerichtete Therapie sehr schwierig 
ist. 
In dieser Arbeit wurde der Krebsphänotyp in verschiedenen KRas-abhängigen 
Modellsystemen untersucht. Zuerst wurde in humanen Krebszelllinien, die aus 
verschiedenen Tumorgeweben stammten, der Phänotyp nach chemischer Inhi-
bition und genetischer Herabregulation von PDEδ untersucht. Alle Zelllinien 
wiesen unterschiedliche Abhängigkeiten von onkogenem KRas auf, wobei ein 
starker Einfluss auf das Wachstum nur bei KRas-abhängigen Pankreas- und 
Lungenkarzinomzellen, aber nicht bei KRas-abhängigen Dickdarmkarzinomzel-
len beobachtet werden konnte. Die jeweiligen Wildtyp-Zellen zeigten zumeist 
kein vermindertes Wachstum. Die genetische Manipulation zeigte exakt die 
gleichen Effekte auf das Zellwachstum wie der neue PDEδ Inhibitor Deltazino-
ne 1, was bedeutet, dass PDEδ ein geeignetes Zielprotein für die gerichtete 
pharmakologische Therapie KRas-abhängiger Tumore ist. 
Als nächstes wurden zwei Zelllinien aus dem Pankreas von transgenen Mäu-
sen, die entweder eine („oncogene addiciton“) oder zwei onkogene Mutationen 
(„synthetic sickness“) tragen, für einen genetischen Screen in Gegenwart von 
chemischen PDEδ-Inhibitoren, verwendet. Die Zelllinien exprimieren entweder 
onkogenes KRas oder onkogenes KRas in Kombination mit mutiertem p53 un-
ter endogener Promoterkontrolle. Wie zu erwarten war die Zelllinie mit der zu-
sätzlichen p53-Mutation resistenter gegenüber dem PDEδ-Inhibitor Deltarasin.  
Diese Arbeit verdeutlicht, dass die Verfügbarkeit von freiem PDEδ unabdingbar 
für das Überleben von KRas-abhängigen Zellen ist. Die Auswirkungen der 
PDEδ-Inhibition auf das Zellwachstum in humanen KRas-abhängigen Zellen 
und die Unterschiede im Verhalten der beiden Mauszelllinien verdeutlichen, 
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dass der Mutationsstatus einen kritischer Faktor für die Empfindlichkeit gegen-
über PDEδ-Inhibitoren und der daraus resultierenden gestörten räumlichen Or-
ganisation von KRas darstellt. Der Erwerb zusätzlicher onkogener Mutationen 
erlaubt es Zellen alternative Signalwege zu nutzen, um auf äußere Einflüsse 
reagieren und so ihr Überleben sichern zu können. 
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2. Abstract 
Oncogenic KRas is associated with a multitude of human cancers, like pancre-
atic, colorectal, and lung carcinomas, concomitant with poor prognosis and sur-
vival. Oncogenic mutations retain Ras in a constitutively active conformation, 
causing sustained activation of downstream signaling cascades, which leads to 
uncontrolled proliferation and survival. Hence, all Ras proteins are interesting 
molecules for targeted cancer therapies. Although the structure and functions of 
Ras proteins are known, it still remains an “undruggable” protein so far. 
In this work, the cancer phenotype upon RNAi and pharmacological inhibition in 
several KRas addiction model systems was elaborated. First, in a panel of hu-
man cancer cell lines, from various tumor origins, the interference with the can-
cer phenotype after PDEδ inhibitor treatment and inducible shRNA-mediated 
downmodulation of PDEδ was studied. These cell lines exhibited different de-
grees of oncogenic KRas dependencies and a strong effect on cell survival 
could only be observed in KRas-dependent pancreatic and lung tumor cells, 
whereas colorectal carcinoma cells with an oncogenic KRas background were 
only slightly affected. Cells with wildtype KRas remained mostly unaffected. The 
new class PDEδ inhibitor Deltazinone 1 and the genetic manipulation of PDEδ 
showed identical effects on cell growth, demonstrating that PDEδ is a valid tar-
get for the pharmacological therapy of KRas-dependent tumors.  
Second, murine pancreatic cancer cells, derived from transgenic mice, with ei-
ther one (oncogene addiction) or two oncogenic mutations (synthetic sickness) 
were used for a synthetic lethal screen in the presence of small molecule PDEδ 
inhibitors. Both cell lines either express oncogenic KRas or oncogenic KRas in 
combination with mutant p53 under the control of endogenous promoters. Here, 
the cell line with the additional loss of p53 fuction seemed to be more resistant 
to PDEδ inhibition by Deltarasin. 
This work demonstrates that the availability of PDEδ is inevitable to ensure sur-
vival of oncogenic KRas-dependent cancer cells. The effects on growth in hu-
man KRas-dependent cell lines and the different behaviors observed in the mu-
rine systems prove that the mutation status is critical for the susceptibility to-
wards PDEδ inhibition and the resulting interference with the spatial organiza-
tion of KRas. The acquisition of additional oncogenic mutations allows for better 
adaptation to changes in the environment and ensures cellular survival. 
 4 
 
3. Introduction 
Cells interpret extracellular stimulation by growth factors or hormones. In order 
to generate an appropriate output, they integrate these signals with intracellular 
information and the subsequent transmission is mediated via complex protein 
signaling networks. It is already known that different stimuli lead to various out-
comes, despite sharing the same network components (Santos, 2007). Such 
structures are highly intertwined, regulated by the directionality of informational 
flow and the connectivity between modules, which create a causal network in 
time and space. 
Signal transduction requires interaction or stimulation, which first causes a cer-
tain signal strength and duration that has to overcome a specific threshold for 
downstream activation of the signaling cascade. The output is dependent on the 
input signal, the transmission into certain signaling pathways, and the spatial 
organization of the network components. To maintain output reproducibility and 
to provide the ability to specifically and rapidly react to a changing environment, 
each module is highly controlled in a dynamic context-sensitive way 
(Kholodenko, 2006). Further, every signal needs to be either terminated at a 
defined point in time to prevent over-activation and misregulation or it has to be 
maintained for sustained or constant activation as with survival information. 
Usually, the programmed cell death (apoptosis) is initiated if the transmission of 
survival signals stops.  
For fine-tuning of transmitted information and the possibility to take alternative 
routes upon activation, non-linear signaling features and a dynamic interplay of 
interaction partners, catalyzing opposing reactions, are neccessary. In this way, 
the existence of negative and positive feedback loops is required to generate a 
robust system (Kitano, 2004). By regulating the directionality of signal propaga-
tion in time and space, according to the input and signal strength, they are inevi-
table for cellular homeostasis. 
Although these networks are robust structures, they are susceptible to external 
and internal perturbations on fragile signaling hubs (Amit, 2007). In this way, 
overexpression of crucial components and the acquisition of oncogenic muta-
tions are highly probable to permanently change the state of a given network. 
As a result, misregulated proliferative information is mediated, which can lead to 
cancer initiation. If the acquisition of an oncogenic mutation provides survival 
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advantages in cells, like higher proliferation rates, increased cellular fitness, or 
lower susceptibility to chemotherapeutics, a tumor becomes more and more 
dependent on this particular mutation (oncogene addiction) with time. Onco-
gene addiction is described as such: the inhibition of a particular oncogene is 
sufficient to halt the neoplastic phenotype in tumors, which rely on a single dom-
inant oncogene for growth and survival (Weinstein, 2006). There are three bio-
logical models for oncogene addiction (figure 1), known as genetic streamlining, 
oncogenic shock, and synthetic lethality (Torti, 2011).  
 
 
 
Figure 1: Schematic representation of the three models of oncogene addiction. (A) Genetic stream-
lining, (B) Oncogenic shock and (C) Synthetic lethality are shown. Figure adapted from Torti, 2011. 
 
In genetic streamlining, the constant genetic drift filters non-essential pathways 
out which do not contribute to an increase in cellular fitness. As a result, the cell 
becomes more susceptible to acute perturbations; thus sudden changes rapidly 
reduce the cellular fitness, causing a collapse. The genetic shock model de-
scribes a single oncogene (e.g. a RTK), which simultaneously triggers survival 
and pro-apoptotic signals. Under normal conditions, the survival signal output is 
dominating. Upon inhibition of the oncogene, an imbalance of the basal signal 
and pro-apoptotic information emerges, which can lead to apoptosis. The model 
of synthetic lethality postulates that two genes are in a synthetic lethal relation-
ship when the loss of one or the other still exerts survival signal but the loss of 
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both leads to death. The concept of synthetic lethality can be extended to the 
situation of mutation acquisition in two oncogenes, which causes increased cel-
lular fitness (synthetic sickness). Isogenic cell lines are therefore compared in 
terms of their response to certain inhibitors in a pairwise manner to determine 
specific target effects (Kaelin 2005).  
 
3.1 Ras proteins are signaling hubs 
This work aims to exploit differences in the cancer phenotype in the context of 
oncogenic KRas addiction between RNAi and small molecule inhibiton in sever-
al in vitro models systems. As the Ras proteins are the biological background of 
this work, one need to first understand their major role in signal mediation under 
normal and pathological conditions.  
Originally, Ras proteins were discovered in 1980 as peripheral membrane pro-
teins localized at the inner leaflet of the plasma membrane (Willingham, 1980). 
In 1982, the RAS (rat sarcoma) gene product was found to be the first onco-
gene (Parada, 1982) and a part of the Harvey virus ( Harvey, 1964) with the 
ability to cause tumor formation in rats. Later, Ras was identified as a GTP-
binding protein (McCormick, 1989), which localizes to the plasma membrane 
(Willumsen, 1984) and harbors lipid modifications (Hancock,1989). It belongs to 
a protein superfamily (Ras superfamily) of 150 related proteins, including Rho, 
Rab, Arf, Rac, and Ran (Wennerberg, 2005). The three well-studied forms of 
Ras, Harvey-Ras (HRas), neuroblastoma-Ras (NRas) (Ulsh, 1984; Ireland, 
1989), and the two splice variants of KRas are members of the Ras subfamily 
(Norton, 1984). 
 
 
Figure 2: The sequence conservation or Ras proteins is shown by a color gradient, ranging from 
red (100% similarity) to yellow (low similarity) on top. The membrane anchor region of the respec-
tive isoforms is depicted below. Farnesylation is shown in red, as it is a permanent modification 
and palmitoylation is represented in blue. Figure apapted from (Bar-Sagi, 2001)  
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All three Ras proteins are structurally similar (figure 2) and belong to the class 
of guanine nucleotide binding proteins (GNBBs), possessing a catalytic G-
domain (Paduch, 2001; Wennerberg, 2005), which binds GTP or GDP with simi-
lar affinities (Vetter, 2001). Ras proteins are 188/189 amino acids in length with 
a molecular weight of 21 kDa. Starting from the N-terminus, the first domain is 
identical in all three isoforms of Ras (KRas, NRas, and HRas) and includes 85 
amino acids. The second domain is built of 80 amino acids, with lower se-
quence identity (90 %). Both regions form the catalytic G-domain (amino acids 
1–165), which includes the guanine nucleotide-binding pocket, the characteristic 
feature of small GTPases. The third domain is named hypervariable region 
(HVR) and terminated by the CAAX box motif (Cox, 2002), bearing the lowest 
sequence identity among all three Ras forms (Valencia, 1991). Where C is a 
cysteine, A stands for aliphatic amino acid and X can be any amino acid. This 
region plays an important role in regulating the biological activity (Rocks, 2005) 
and spatial organization of Ras (Hancock, 1989; Hancock, 1990; Lorentzen, 
2010; Schmick, 2014). 
A common feature of GTP-binding proteins is their switch-like behavior, con-
trolled by GDP/GTP cycling. The transition between GTP-loaded and GDP-
loaded states of Ras is known as the GTPase cycle (figure 3), and occurs in 
response to activation of GEFs (Guanine-nucleotide exchange factors) and 
GAPs (GTPase-activating proteins) from upstream signaling events. In the 
GDP-bound state, GNBBs are inactive. Upon GTP-binding, they undergo con-
formational changes in the G-domain, resulting in an active state.  
In a cell, the cytoplasmic GTP concentration has a tenfold higher affinity to be 
bound when compared to GDP (Antonarakis, 1998; Zhang, 2005). GDP is inter-
changeable with GTP by GEFs. The exchange from GDP to GTP causes a con-
formational change in the switch 1 and switch 2 region (loaded-spring mecha-
nism), forming an effector loop and the -phosphate of GTP interacts with Thr 
35 and Gly 60 of the respective region (Vetter, 2001). The P-loop 
(GXXXXGKS/T, aa 10–16) forms a polyanion hole (Dreusicke, 1986), neutraliz-
ing the negative charge of the -phosphate of GTP. To counteract activation, 
GTPase-activating proteins (GAPs) amplify the GTPase activity 100,000 fold, 
resulting in a fast hydrolysis of GTP to GDP (Gideon, 1992), promoting the for-
mation of the inactive form (Bernards 2004). The hydrolysis reaction is Mg2+-
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dependent and requires the formation of a stabilized transition state where the 
nucleophilic attack of a water molecule on the -phosphate of GTP is possible 
(Vetter, 2001). 
This core effector region of Ras (aa 32 and 40) is essential for the interactions 
between GAPs and downstream effectors as the changes in the tertiary struc-
ture allow to distinguish between the “off” (GDP-bound) and “on” (GTP-bound) 
state. As a side effect of effector binding, the dissociation of GTP is diminished 
because the GTP-bound form of the GTPase is stabilized. GEFs and GAPs not 
only exhibit different expression patterns and localizations, but also differ in their 
regulations and activation by a multitude of cellular receptors and proteins. 
 
 
Figure 3: The GTPase Cycle. Ras is a molecular switch and transitions between a GTP-bound and 
GDP-bound state. GEFs catalyze the nucleotide exchange reaction, whereas GAPs perform the 
opposed reaction. Ras becomes active in the GTP-bound state and can bind to downstream effec-
tors of the signaling cascade 
 
In summary, Ras can exist in two states, the active GTP-bound and the inactive 
GDP-bound state, caused by the dynamics of the GTPase cycle (figure 2). In 
the active conformation, Ras functions as a trigger to activate downstream sig-
naling proteins. Ras proteins connect a multitude of upstream signals to an 
even larger variety of downstream effectors, thereby functioning as signaling 
hubs (figure 4). The cellular outcome ranges from cell proliferation, cell cycle 
progression, migration, cytoskeletal remodeling, senescence, and apoptosis 
(Vojtek, 1998; Shields, 2000; Adjei, 2001; Downward, 2003; Karnoub, 2008; 
Fedorenko, 2013). Consequently, the acquisiton of an oncogenic mutation in 
the Ras proteins is concomitant with aberrant downstream signaling and asso-
ciated with a multitude of cancers. Oncogenic mutations in all isoforms frequent-
ly occur close to the active site, either in the P-loop at position 12 (G12V/D) or 
13 or in the switch 2 region (Q61L), where it blocks the GAP-mediated hydroly-
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sis reaction from GTP to GDP (Seeburg, 1984; Trahey, 1987; John, 1988; 
Tong, 1989; Prior, 2012). Such mutations abolish the formation of a transition 
state for GTP-hydrolysis and lead to an accumulation of GTP-bound Ras. For 
sterical reasons, in case of Ras G12V/D, no other residue is possible and this 
mutation interferes with the formation of the transition state and the intrinsic 
GTPase activity (Privé, 1992). 
 
 
Figure 4: Ras as the central node converges signaling information from upstream receptor activa-
tion and transmits it via different pathways, including MAPK and PI3K/Akt. The outcome ranges 
from growth and survival to invasion and apoptosis. Figure adapted from (Fedorenko, 2013) 
 
Ras is activated at the plasma membrane by upstream growth factor stimulation 
and mediates proliferative information through the Ras-Raf-MAPK (Mitogen-
activated protein kinase) pathway (Pearson, 2001) and survival or death signal-
ing via the PI3K/Akt (Phosphatidylinositol 3-kinase) pathway (Marte, 1997). A 
plethora of other downstream effectors like the stress-response pathway via 
MEKK1, cell-cycle regulation via Ral, Raf, and PI3K (Gille, 1999), actin cyto-
skeleton remodeling via Ral and Rac, and PLCε regulation (Wing, 2003) have 
been reported to be activated (figure 4). In general, the recruitment of cytosolic 
factors to the plasma membrane is one possibility to potentiate the signaling 
outcome as it causes a dimensionality reduction in their diffusional space, which 
makes the subsequent reaction more probable (Schmick, 2014). 
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There are three classes of Ras effectors, which either harbor a Ras-binding 
domain (RBD) or the structurally similar Ras-associating domain that allows for 
interaction with the Ras effector loop. 
The first class contains proteins with a RBD-motif, including Raf family mem-
bers and scaffold proteins like CNK (connector enhancer of kinase suppressor 
of Ras 1) and KSR (kinase suppressor of Ras 1). Briefly, these proteins activate 
Mek, the dual-specificity MAPK. Mek phosphorylates and thereby activates Erk1 
and Erk2, resulting in transcriptional activity for cell growth and cell cycle entry. 
Another interaction partner of Erk is MNK (MAPK-interacting ser/thr kinase), 
which contributes to cell growth control. Erk also phosphorylates and activates 
RSK (ribosomal protein S6 kinase) a downstream target of mTor (mammalian 
target of rapamycin), thereby connecting the mTor pathway to Ras/MAPK sig-
naling. (Sengupta, Peterson, and Sabatini 2010) 
The serine/threonine kinase mTor is an integrator of mitogenic and nutrient in-
puts and senses nutrient, oxygen and energy levels of the cell (Hay, 2004; 
Sarbassov, 2005; Jewell, 2013). The downstream regulators for protein synthe-
sis of mTor are the eukaryotic initiation factor 4E-binding protein (4E-BP1) 
(Poulin, 1998) and S6 kinase (RSK). Upon growth factor stimulation, mTor-
activating signals are mediated via the PI3K/ pathway and act both downstream 
and upstream of Akt, thereby connecting Ras/MAPK, mTor and PI3K/Akt signal-
ing. Akt phosphorylates and thereby inactivates Tuberin (TSC2, Tuberous Scle-
rosis Complex 2), a negative regulator of mTor (Inoki, 2002). Akt phosphoryla-
tion of TSC2 releases TSC inhibition of the Ras family member RheB (Ras 
homolog enriched in brain), which then accumulates in its GTP-bound state and 
activates mTor (Sengupta, 2010). This double negative feedback loop from Akt 
to mTor via TSC2 and RheB causes mTor activation. With regard to other sig-
naling pathways, TSC2 is also a direct substrate of Erk and RSK. 
The second protein family, known to directly interact with Ras is PI3K. The cata-
lytic subunit p110 can directly bind to Ras (Samuels, 2005). PI3K pathway mu-
tations occur in 30 % of all cancers (Luo, 2003). Among the PI3K pathway pro-
teins, PTEN (PI3K-phosphatase with tensin homology) is the second most 
commonly tumor suppressor, after p53, which is lost during tumorigenesis 
(Bonneau, 2000). The third group of Ras effectors consists of RalGDS and 
PLCε, which harbor RA domains (Ras-associating domains). 
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All the above mentioned pathways can be simultaneously activated, as they are 
tightly controlled by the high degree of connections between individual signaling 
components and globally by the existence of feedback loops to maintain cellular 
homeostasis under normal conditions. As shown for mTor, upstream signals 
from Ras and PI3K are integrated to only allow for cell proliferation under envi-
ronmentally favorable conditions (Wullschleger, 2006). Instead, cancer cells 
promote growth and survival under inappropriate conditions. In case of Ras, any 
mutation that leads to constitutively active conformation causes a hyper-
activation of downstream effectors, resulting in abnormal growth or enhanced 
survival. In this way, the uncontrolled Ras activity can lead to pathophysiological 
consequences, including cancer. The activation signals generated by oncogenic 
Ras could be inhibited by targeting the GTPase cycle with specific drugs, mak-
ing it an attractive target for pharmaceutical research. Until now, Ras proteins 
remain an “undruggable” target, as any drug design failed because of toxicity 
and pleiotropic effects (Cox , 2002; Carón, 2005). 
Apart from oncogenic Ras, several other components like PI3K or EGFR are 
also frequently found to be misregulated in cancers. The complexity of all these 
networks has to be understood in order to spot pathological alterations and to 
drive the cell to a senescent or apoptotic state. Interestingly, oncogenic Ras 
mutations and mutations in other components of the MAPK signaling pathway, 
like mutant B-Raf, have been shown to be mutually exclusive in malignant mel-
anoma (Davies, 2002). Oncogenic KRas mutations are frequently found in early 
stages of tumor progression. Hence, the deregulation of Ras-mediated signaling 
is essential for tumorigenesis. Similar to oncogenic B-Raf, mutations in Ras 
family members and loss of PTEN are mutually exclusive in mice and human 
(To, 2005). Nonetheless, simultaneous alterations in more than one signaling 
component have been demonstrated for solid tumors where the overexpression 
of EGFR-related genes in combination with oncogenic KRas are good predic-
tion markers whether a certain chemotherapeutical strategy can be applied 
(Amado, 2008). 
To focus on relevant signaling output with regard to this work, two opposing 
signaling pathways, namely MAPK and p53, will be discussed further in the fol-
lowing sections. 
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3.1.1 Ras activates the MAPK pathway 
The MAPK (mitogen-activated protein kinase) pathway, a downstream signaling 
cascade of Ras, translates extracellular input into gene expression. The diverse 
output can result in cell growth, migration, division, and survival (Raman, 2007). 
The MAPK pathway can be activated by several extracellular stimuli (growth 
factors, hormones) each binding to a different receptor (Wolf, 2002). 
One such ligand is Epidermal Growth Factor (EGF), which specifically activates 
the receptor tyrosine kinase (RTK) EGFR (epidermal Growth Factor Receptor). 
Upon EGF-stimulation, EGFR undergoes dimerization and subsequent trans-
phosphorylation on specific tyrosine residues in its C-terminal domain by its in-
trinsic kinase activity. These phosphorylated tyrosine residues serve as recogni-
tion sites (Ullrich, 1990; J. Schlessinger, 1992; Schlessinger, 2000) for various 
adaptor proteins, like Grb2 (Schlessinger, 2003; Batzer, 1994). Following re-
cruitment of Grb2, SOS (Son of Sevenless, a guanine nucleotide exchange fac-
tor (GEF)) is activated to exchange GTP for GDP on Ras (Jorissen, 2003). The 
MAPK module is activated by GTP-bound Ras and composed of the kinases 
Raf (MAPKKK), Mek (MAPKK), and Erk (MAPK). Proliferative signals are 
transmitted in a stepwise manner by phosphorylation and activation of the fol-
lowing kinase (figure 5). 
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Figure 5: Schematic representation of the EGF-mediated EGFR activation and signal transmission 
to the Raf-Mek-Erk signaling cascade via active Ras. After growth factor stimulation, Ras is acti-
vated and consecutively each kinase activates the downstream kinase by phosphorylation in a 
cascade manner. Phosphorylated Erk1/2 can either translocate to the nucleus to activate the tran-
scription machinery or phosphorylate cytosolic substrates. 
 
More precisely, Ras alters its conformation from an inactive (GDP-bound) to an 
active state (GTP-loaded). The GTP-bound state favors the binding of effector 
proteins like the cytosolic serine/threonine kinase Raf (Kolch, 2000). The Ras-
binding domain (RBD) of Raf interacts with Ras-GTP thereby recruiting Raf to 
the plasma membrane. For Raf-1 it was shown to require membrane-bound 
Ras for its activation (Morrison, 1997). The Ras-mediated concentration of Raf 
on the plasma membrane facilitates dimerization and subsequent Raf activation 
(Hu, 2013; Nan, 2013).  
Phosphorylated Raf activates Mek, a dual specificity tyrosine/threonine kinase, 
by phosphorylation (Seger, 1995). Mek then activates another downstream ser-
ine/threonine kinase Erk by phosphorylation. Erk is the terminal protein in the 
MAPK pathway. ERK1 and ERK2 (extracellular-signal-regulated kinase) are 
serine/threonine kinases, with a molecular weight of 44 and 42 kDa, respective-
ly. For full Erk2 activity, a conserved Thr(183)-Xxx-Tyr(185) motif in the activa-
tion loop has to be phosphorylated on both residues by active Mek (Kolch, 
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2000), causing Mek-Erk dissociation and Erk homodimerization (Wolf, 2002; 
Seger, 1995). 
Erk has a broad spectrum of cytosolic and nuclear substrates, such as tran-
scription factors, protein kinases and phosphatases, as well as cytoskeletal and 
scaffold proteins (Yoon, 2006). Erk dimers translocate from the cytosol into the 
nucleus (Fukuda, 1997). This nuclear accumulation happens within 5-15 
minutes and induces transcription (Adachi, 1999). How the translocation func-
tions in detail is still not fully understood. Regarding the existence of a nuclear 
translocation signal (NTS), which facilitates nuclear import of Erk, contrary opin-
ions exist in literature (Chuderland, 2008; Lidke, 2010). Although this process is 
phosphorylation-dependent, kinase activity is not required because kinase-dead 
mutants of Erk2 also accumulate in the nucleus (Khokhlatchev, 1998). Nonethe-
less, the nuclear translocation is a requirement in terms of transcription induc-
tion and proliferation (Brunet, 1999). Erk phosphorylates S6-kinase (RSK) and 
the ternary complex factors (TCFs), Elk-1, Net-1, and Sap (Yoon, 2006). Elk 
initiates the expression of several genes required for proliferation. ERK1/2 acti-
vation and its localization are dynamically controlled by continuous phosphory-
lation and dephosphorylation cycles, which can be differentially regulated upon 
stimulation (Costa, 2006; Santos, 2007). A variety of substrate genes is under 
the control of a serum-response-element (SRE). RSK phosphorylates the serum 
response factor (SRF), which first binds to one of the TCF proteins and then to 
the SRE in the promoter of immediate early genes, like Fos and Myc (Anjum, 
2008; Buchwalter, 2004). Active Erk and Erk-mediated signaling can be inacti-
vated by serine/threonine phosphatases, tyrosine phosphatases and dual speci-
ficity phosphatases DUSP, (5, 6, 7 and 9) (Owens, 2007). 
The MAPK pathway is a robust and conserved network and homeostasis is 
maintained by the dynamic interplay of positive and negative feedback loops, 
which account for the variety of output signals. Using the interaction between 
Ras and its upstream GEF as an example, SOS not only activates Ras, but ex-
hibits an allosterically elevated activity when active Ras is present (Waters, 
1995), asserting a positive feedback on itself. Hence, SOS functions as a GEF 
as well as an effector for Ras proteins. Another example is the interplay be-
tween Raf, Mek and Erk. Erk as the terminal node mediates on one hand a pos-
itive feedback loop on Mek, thereby activating itself (signal amplification). On 
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the other hand, there is the negative feedback on Raf, to silence the upstream 
activation signal, promoting stability of the system (Santos, 2007). 
As may be imagined, the presence of oncogenic Ras triggers MAPK-mediated 
proliferative signals, causing uncontrolled cell growth and migration, essential 
features of tumorigenesis. As Erk is downstream of Ras, Raf, and Mek, several 
inhibitors and sensors (Murphy, 2002; Harvey, 2008; Toettcher, 2013) have 
been developed. Moreover, commercially available kinase activity-based read-
out kits are available to monitor Erk activation as a proof of upstream activation. 
 
3.1.2 The p53 protein functions as a tumor suppres-
sor 
Aside from the MAPK pathway, several other signaling routes are affected by 
active Ras, like the p53 pathway. In contrast to the oncogenic nature of Ras, 
p53 is a tumor suppressor, which functions as a checkpoint for abnormal signal-
ing and is frequently mutated in a large number of cancers. 
The p53 gene was first discovered in 1979 (Lane, 1979) and 10 years later it 
was confirmed that the p53 protein plays a key role in several human cancers 
(Harris, 1993), functioning as the “Guardian of the genome” (Sigal, 2000). The 
p53 gene is a tumor suppressor, encoding for a 393 aa protein, whose signaling 
pathway integrates important checkpoints to regulate cell growth and apoptosis 
after intrinsic or extrinsic stresses (Jin, 2001; Vogelstein, 2000; Vousden, 2002). 
Regardless of the type of stress, p53 activation either results in cell cycle arrest, 
cellular senescence (Hayflick, 1965), DNA repair or apoptosis (Jin, 2001; 
Vousden, 2002). 
In response to stress, p53 is posttranslationally modified by phosphorylation, 
acetylation, methylation, ubiquitination or sumoylation (Appella, 2001). These 
PTMs raise the half-life of p53 from 6-20 min to hours and cause a 3-10-fold 
increased protein concentration. Moreover, the binding to specific DNA se-
quences, which regulates the transcription of genes, is enhanced. Besides the 
single-cell level, direct communication with neighboring cells by secretion of 
proteins that alter the cellular environment is also facilitated by p53 (Harris, 
2005). 
The p53 pathway can be divided into five steps. First, input is generated by ac-
tivating stress signals, which are integrated by mediators. Several proteins are 
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activated that interact with p53 thereby modulating its stability (Jin, 2001). This 
either leads to transcriptional activation or protein-protein interactions resulting 
in growth arrest, senescence, apoptosis or DNA repair (figure 6). 
 
 
Figure 6: Upon DNA damage, dsDNA breaks and triggers the activation of ataxia-telangiectasia 
mutated (ATM), a kinase, which phosphorylates CHK2 kinase via ATR and CHK2. CHK1 and 2 
phosphorylate p53 thereby stabilizing it. Serine 15 and 20 are important for its stabilization. MDM-2 
and MDM-4 bind to the transcriptional activation domain, thereby inhibiting p53 transactivation, 
MDM also functions as E3 ubiquitin ligase, targeting for proteasome-mediated degradation. Phos-
phorylation allows interaction with downstream targets to initiate apoptosis, cell cycle arrest, DNA 
repair or senescence (Figure adapted from Bieging, 2014) 
 
The p53 network is tightly controlled by 10 feedback loops (positive or nega-
tive). Under normal conditions, p53 levels are downregulated by MDM-2, Cop-1, 
Pirh-2 or JNK (negative regulators) that promote constant degradation (ubiqui-
tin/proteasome pathway). These genes are upregulated by p53 itself, keeping 
the p53 protein level low (negative feedback) (figure 6). Further negative regula-
tors are p73 delta N, cyclin G, Wip-1 and Siah-1. Upon stress, p53 protein lev-
els are elevated by inhibition of the interaction with MDM-2. Second, a series of 
modulators (kinases, acetylases) will activate the transcriptional activity. Posi-
tive feedback loops are transmitted via PTEN-Akt, p14/19 Arf, and Rb. 
The specific DNA-binding activity of p53 is mediated via the carboxy terminal 
tetramerization domain and was also shown to be triggered by phosphorylation 
(Hupp, 1992), ss DNA, deletion/truncation (30 aa), and interaction with cellular 
proteins (Hupp, 1992; Jayaraman, 1995). The protein binding occurs through a 
p53-responsive element (p53 RE), which is found either in the promoter or in 
the intron of target genes. The p53 RE monomer unit is composed of 
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RCWWGYYY, where R is a purine, W is either A or T, and Y is a pyrimidine. 
Thus, two 10 bp sequences with a spacer of 0-13 nucleotides form the regulato-
ry sequence for p53-responsive genes (Riley, 2008). Subsequent to p53 te-
tramer binding, transcription of target genes is initiated and results in activation 
of multiple proteins, acting in different pathways to promote tumor suppression 
(figure 7). 
The loss of p53 function by mutation or deletion is a common feature of 
tumorigenesis. As such, these mutations mostly result in the expression of p53, 
which has lost its wild-type functions. In almost 90 % of all human tumors, it 
commonly exhibits missense mutations, resulting in a stable mutant p53 protein, 
which lacks its specific DNA binding function and accumulates in the nucleus 
(Soussi, 2001). Such missense mutations occur in <50 % of PDAC cases 
(Rozenblum, 1997). Cells with a dominant-negative regulation of mutant p53 
acquire oncogenic properties (gain-of-function), independent of the status of 
wild-type p53 (Petitjean, 2007; Brosh, 2009). Such gain-of function mutants ac-
tively promote cancer (Blandino, 1999; de Vries, 2002; Brosh, 2009; Dittmer, 
1993). They exhibit an enhanced tumorigenic potential, enhanced 
drug/chemotherapy resistance, and altered transcriptional activities, compared 
to cells that lack p53. 
Patients with Li-Fraumeni syndrome have a mutant TP53 allele and are more 
susceptible to cancer (Vousden, 2009). As shown in animal models, the pres-
ence of one mutant allele leads to enhanced chemo-resistance and a broader 
tumor spectrum. Among the different tumor types, carcinomas, sarcomas, and 
lymphomas are predominant, concomitant with increased metastasis and ge-
nomic instability (Lavigueur, 1989; Olive, 2004; Liu, 2010). In general, mutant 
p53 drives invasion, migration, scattering, angiogenesis, stem cell expansion, 
survival, proliferation, and tissue remodeling by signal transmission through dif-
ferent pathways. The resulting alterations in the DNA-binding ability change the 
regulation of gene expression or the interactions with different proteins and 
transcription factors. 
As shown in figure 7, p53 mutants can be divided into structural mutants, which 
cause unfolding of the protein, and DNA-contact mutants, which change the 
amino acid composition critical for DNA binding (Sigal, 2000). 
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Point mutation R172H (structural mutant) and R270H (contact mutant) (codons 
175 and 273 in humans) engineered in mice under endogenous locus are mod-
el systems of Li-Fraumeni Syndrome (p53 R270H/+). With time, they evolve allele-
specific tumors like osteosarcomas, breast cancer, soft tissue sarcoma and leu-
kemia. In combination with oncogenic KRas, they reflect late-stage pancreatic 
cancer with metastatic properties (Olive, 2004).  
 
 
Figure 7: Structure of p53. The p53 protein has two N-terminal transcriptional activation domains 
(TADs), followed by a proline-rich domain (PRD), a DNA-binding domain (DBD) and a 
tetramerization domain (TET) and the C-terminal region, rich in basic residues (Basic). The most 
frequent mutations are shown as either structural or contact mutants. After tetramer formation and 
binding to DNA, several genes are regulated, grouped into functional groups as depicted in the 
boxes. (Figure adapted from Bieging, 2014)  
 
Due to the complex topology of the network, p53 was found to share signaling 
routes of the Ras/MAPK pathway. There is evidence, that structural mutant p53 
can interact with the cell cycle regulator BTG2, preventing it from deactivating 
HRas (Solomon, 2012). Upon phosphorylation of p53 at serine 33 and 46 by 
p38 MAPK, p38 MAK is itself phosphorylated, regulated by the MAPK pathway. 
Wip-1 phosphatase inactivates p38 MAPK and is a p53-regulated gene, which 
forms a negative feedback loop by connecting p53 and Ras (Takekawa, 2000). 
Heat-shock proteins, activated Ras and PTEN have been shown to stabilize 
p53 (Suh, 2011). Additionally, the introduction of oncogenic Ras into primary 
cells was shown to cause p53-dependent senescence (Bates, 1998; Eliyahu, 
1984; Parada, 1984). Nonetheless, oncogenes like Ras and Myc are usually 
detected by the p53 checkpoint and such transformed cells are subsequently 
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killed, demonstrating its tumor suppressor function. The dual role of p53 is re-
flected by the ability to detect mutations in cell cycle regulators and by blocking 
the progression of cell cycle, affecting a broad range of outcomes. 
 
3.2 The KRas oncogene 
During tumor progression, KRas is the most frequently mutated isoform among 
the Ras proteins (Allegra, 2009; Aguirre, 2003) and present in 30 % of all can-
cers (Forbes, 2011).  
Discovered in 1983, the human KRAS gene was detected in the genomic DNA 
of human LX-1 lung carcinoma cells and found to be a homologue of two retro-
viral oncogenes (Kirsten Rat Sarcoma Virus and Murine Sarcoma Virus), relat-
ed to rodent sarcoma virus genes (Shimizu, 1983). One year later, it was shown 
that the gene product can also result in an abnormal form of the p21 protein, 
which is able to transform NIH3T3 cells. This aberrant gene product predomi-
nantly occurred in carcinoma tissue and was therefore linked to an abnormal 
state of activation (Norton,1984). Following these first observations, KRas was 
found to initiate signaling cascades and mediate information from the cell pe-
riphery to the nucleus, resulting in cell differentiation, proliferation, apoptosis, 
and cell migration/chemotaxis (Rajalingam, 2007; Zuber, 2000; Campbell, 
1998). Moreover, it induces changes in the cytoskeleton and consequently af-
fects cell shape, adhesion, and migration (Esser, 1998). KRas consists of 188 
amino acid residues, divided into four domains with a molecular mass of 
21.6 kDa. Moreover, it was shown to be the only isoform, which is essential in 
mouse embryogenesis. Neither HRas nor NRas knockouts have detectable side 
effects on the development of mouse embryos, whereas a KRas knockout is 
embryonic lethal at 12-14 days, concomitant with late-onset growth and 
hemopoietic defects (Johnson, 1997; Koera, 1997).  
The human genome has two copies of the KRAS gene, KRAS1 and KRAS2, 
(McGrath, 1983), which are localized at chromosomes 6p11-12 and 12p11.1-
12.1 (Popescu, 1985). The splice variant KRas4A undergoes additional 
palmitoylation by palmitoyltransferase upstream of the CAAX motif. KRas4B is 
the predominant splice variant of KRAS2 (Pan, 1990) and there is no detectable 
palmitoylation of this splice variant (Hancock, 1989). The KRAS4B gene product 
was exclusively used in the present work and will be further named KRas.  
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It has been demonstrated that the wild-type KRAS gene is frequently replaced 
by mutant KRAS during tumor progression in many types of cancer (Allegra, 
2009; Aguirre, 2003). Once the KRAS gene mutates, it acquires oncogenic 
properties and seems to be involved in the development of various human can-
cers (Kranenburg, 2005; Barbacid, 1987; Malumbres, 2003). 
Such oncogenic transformations are widely present in pancreatic cancer (90 %), 
colorectal carcinomas (40-50 %), and lung carcinomas (30-50 %) (Bos, 1989; 
Schubbert, 2007a; Schubbert, 2007b). The acquisition of a mutant KRAS allele 
has been observed in both, human and mouse tumors, indicating that the ab-
sence of normal alleles may facilitate transformation by one copy of the onco-
genic KRAS allele (Hingorani, 2003). Like the other Ras proteins, KRas needs 
to be in the active GTP-bound state to be able to interact with downstream ef-
fectors. As mentioned before, oncogenic KRas (KRasG12V) has an impaired 
GTPase activity. The G12V mutation causes a sterical clash in the active site 
and locks the protein in a permanent GTP-bound state, as the GAP-mediated 
GTP hydrolysis reaction is prevented (Vetter, 2001). As a consequence, the 
protein is constitutively active and permanently transmits proliferative and sur-
vival signals. Since KRas functions as the signal integration point for prolifera-
tive and survival information, this leads to hyper-activation of important cellular 
pathways, like MAPK activation. Such mechanisms are regularly found in can-
cer. Regarding the constitutively active mutant G12V, recent research shows 
that KRas is not constitutively active, rather readily activated by upstream stimu-
li (Huang, 2014), leading to a prolonged strong KRas activity. 
In more than 90 % of reported pancreatic adenocarcinomas, constitutively ac-
tive mutations in the KRAS gene were found (KRasG12D/V). At the time of di-
agnosis, pancreatic adenocarcinomas harbor oncogenic KRas mutations 
(>80 %) with an average survival rate of the patients below 6 months (American 
Cancer Society). Tobacco exposure (Hruban, 1993), as well as coffee drinking 
(Porta, 1999) and milk, butter, and alcohol consumption (Morales, 2007) were 
reported to correlate with pancreatic cancer bearing oncogenic KRas. The 
growth and survival in several pancreatic cell lines were shown to be KRas-
dependent (Singh, 2009; Collisson, 2011). KRas mutations are frequent in early 
cancer stages and play an important role in PanIN (pancreatic intraepithelial 
neoplasia) formation, whereas an additional mutation in the tumor suppressor 
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p53 characterizes late stage cancer (Hingorani, 2003; Aguirre, 2003; Hingorani, 
2005; Hezel, 2006). Mouse models with inducible KRas G12D demonstrate that 
fibrotic stroma is formed and maintained after induction. Inactivation of mutant 
KRas, accompanied with p53-/+ results in tumor regression, pointing towards 
the adaption and subsequent addiction of oncogenic KRas signaling (Collins, 
2012). 
The second highest occurrence of KRas mutations, around 50 % of all cases, is 
found in colon cancer (Bazan, 2002). In earlier studies, cancer invasion was 
shown to be enhanced in fibroblasts expressing oncogenic KRas, accompanied 
with increased adhesiveness and altered polarization (Liao, 2003). Moreover, 
upregulated carcinoembryonic antigen (CEA) expression and disturbance of 
epithelial cell polarization after oncogenic KRas expression was observed (Yan, 
1997; Otori, 1997). 
The development of CRC is categorized in three stages with different probabili-
ties of oncogenic KRas mutation. Stage 1 characterizes the development of a 
small, benign tubular adenoma or polyp with sporadic KRas mutations. Stage 2 
is defined as a more aggressive phenotype with patches and definite carcinoma 
cells. In case of stage 3, the cells start invading other tissues. KRas mutations 
occur in adenoma and carcinoma tissue, with carcinoma tissues being more 
frequently mutated (Forrester, 1987; Vogelstein, 1988).  
KRas mutations occur in 10-30 % of lung cancers, accompanied with poor 
prognosis (Broermann, 2002) and a history of smoking. Despite the fact that 
NSCLC (non-small cell lung cancer) is known to frequently evolve activating 
EGFR (epidermal growth factor receptor) mutations, oncogenic KRas was de-
tected in 21 % of NSCLC-tumor samples (Eberhard, 2005). Oncogenic KRas is 
inevitable for tumor cell survival at all stages of lung adenocarcinoma. Further, 
the presence of an additional mutation or loss of tumor suppressor function re-
quires mutant KRas (Fisher, 2001). 
Small molecule tyrosine kinase inhibitors (TKis) like Gefitinib (Iressa®) and 
Erlotinib (Tarceva®) are used as the second line therapy in patients with 
NSCLC after failure of standard chemotherapy. In the presence of mutant 
KRas, a poorer response and shortened survival is observed. Thereby onco-
genic KRas functions as a prediction marker to elucidate resistance to targeted 
therapy after EGFR inhibition (Massarelli, 2007; Katzel, 2009). In colorectal car-
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cinomas, the KRas status has to be evaluated carefully, because treatment with 
monoclonal antibodies targeting EGFR, Cetuximab (Erbitux®) and 
Panitumumab (Vectibix®), fails when mutant KRas is expressed (Lièvre, 2006; 
Amado, 2008) . Even the “gold standard” for CML (chronic myeloid leukemia) 
Imatinib (Glivec®) was found to be ineffective in patients with frequently ex-
pressed oncogenic KRas (Agarwal, 2008). In order to derive benefit from 
EGFR-TKis, the status of KRas as a biomarker should be considered for target-
ed inhibition. According to Singh et al., (Singh, 2009), cancers can be divided 
into oncogenic KRas dependent and independent which would give information 
about therapeutic prognosis. Additionally, KRas was found to dominantly acti-
vate Raf kinase, a downstream effector, while the other Ras proteins activate 
another branch of downstream signaling, the PI3K pathway (Phosphoinosite-3 
kinase), and causing survival.  
There have been attempts to inhibit oncogenic KRas by farnesyltransferase in-
hibitors (FTIs), which were demonstrated to work in vitro and in xenografts 
(Omer, 1997; A, 1997), shown to inhibit anchorage-independent growth of both 
KRas-transformed mouse fibroblasts and human tumor cells with KRas and 
NRas mutations, but failed in clinical studies (Blum, 2005). FTIs inhibit the C-
terminal farnesylation on Ras proteins without affecting geranyltransferase ac-
tivity, which might preserve Ras activity (Lerner, 1997) by taking over the catal-
ysis of lipid modifications. 
 
3.3 Lipidated Ras proteins localize to different cellular 
compartments 
Apart from their GTPase activity and plasma membrane localization, all three 
Ras isoforms harbor lipid modifications, which are essential for their function 
and specific localization. This is achieved by posttranslational lipidation in the 
hypervariable region, an additional feature of the majority of Ras superfamily 
proteins (Hancock, 1989; Hancock, 1990).  
After ribosomal protein translation, Ras proteins are irreversibly farnesylated by 
farnesyltransferase at the cysteine residue of the CAAX-box motif (Gelb 1997). 
Farnesyltransferases and geranylgeranyltransferase I recognize the CAAX-
sequence and catalyze the binding of isoprenoids (farnesyl or geranylgeranyl) 
to the cysteine residue by forming a covalent thioether bond. At the cytosolic 
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surface of the ER, (endoplasmic reticulum) the AAX motif is cleaved by the local 
protease Rce1 (Ras-converting enzyme 1) and the C-terminal carboxyl residue 
is subsequently methylated by Icmt (Rajalingam, 2007). KRas4B is directly 
transported to the plasma membrane whereas HRas, NRas, and KRas4A are 
further modified (Swarthout, 2005), before reaching the plasma membrane. 
In general, lipid modifications are either irreversible, or reversible. Irreversible 
lipidations remain on a functional protein and are only removed by proteasomal 
degradation. There are three kinds of irreversible lipid modifications in eukary-
otes: N-linked acyl groups in case of myristoylation (Martin, 2011), S-linked 
isoprenoids (Hougland, 2009), like farnesylation of Ras proteins, and O-linked 
cholesterols (Milenkovic, 2010). 
HRas, NRas and KRas4B undergo two types of lipidation: an irreversible 
farnesylation at the C-terminal cysteine of the CAAX-Box motif and a reversible 
(figure 2). Briefly, HRas is doubly palmitoylated (position C181 and C184), 
which correlates with a more prominent plasma membrane localization as com-
pared to NRas. N-Ras contains only a single S-palmitoylated cysteine residue 
(position C181). The KRas4A splice variant is mono-palmitoylated and the 
splice variant KRas4B is only farnesylated (Hancock, 1989).  
Due to their lipid modifications, all Ras isoforms localize to the plasma mem-
brane and endomembranes. The degree of association with endomembranes 
differs among the Ras isoforms N>H>KRas (Choy, 1999). HRas and NRas ad-
ditionally populate the Golgi apparatus mediated by localized 
palmitoyltransferases activity, thereby locally enhancing their membrane affinity 
(Rocks, 2006).  
 
3.4 The GDI-like solubilization factor PDEδ 
It has been proposed that intracellular Ras trafficking involves prenyl-binding 
proteins (Nancy, 2002; Hanzal-Bayer, 2002). PDEδ, which functions as a GDI-
like solubilization factor for farnesylated proteins (Chandra, 2012; Zhang, 2004), 
by solubilizing these membrane-anchored proteins, thereby enhancing their ef-
fective diffusion in the cytosol (Schmick, 2014a; Schmick, 2015). 
PDEδ (PDE6D) is a soluble 17 kDa protein, which was first identified as the 
fourth subunit of rod cell-specific photoreceptor cGMP phosphodiesterase 
(PDE6) (EC 3.1.4.35) located in retinal tissue. It was discovered as a co-
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precipitate of rod PDE (Gillespie, 1989) and found to play a major role in the 
phototransduction cascade. The holoenzyme is a heterodimer, consisting of two 
α- and β-subunits, regulated by two -subunits (Baehr, 1979; Fung, 1990). The 
α- and β-subunits are post-translationally modified with a farnesyl (C15) or 
geranylgeranyl (C20) moiety, localizing PDE6 to the membrane. PDEδ solubil-
izes PDE from the rod outer segment disc membrane, without affecting its cata-
lytic activity (Florio, 1996). PDEδ is expressed in various tissues and in eyeless 
invertebrates such as C. elegans, suggesting additional functions besides the 
solubilization of PDE in the eye (Li, 1998).  
The core domain structure of PDEδ shows an immunoglobulin-like β-sandwich 
fold with two β-sheets that pack against each other, followed by an N-terminal 
α-helix. The structural comparison with RhoGDI (guanine-nucleotide dissocia-
tion inhibitors) gave the best hit (Z-score 9.8). RhoGDI solubilizes C-terminally 
prenylated proteins (Rac, Rho, and Cdc24) from cellular membranes. Although 
the sequence homology is very low, the fold and also the composition and posi-
tion of specific residues, which form the inner surface of the lipid-binding pocket 
are identical, indicating the common features of both PDEδ and RhoGDI 
(Hanzal-Bayer, 2002). Nonetheless, PDEδ lacks an N-terminal helix-loop-helix 
motif, which allows interactions with the switch region of GTPases, meaning it 
has no binding preference for the nucleotide state of its interaction partner 
(Nancy, 2002; Hanzal-Bayer, 2002). Instead, PDEδ is a non-selective prenyl-
binding protein, which targets hydrophobic prenylated C-termini of a variety of 
polypeptides with a stoichiometry of 1:1. Notably, it strongly interacts with 
farnesyl but to a lesser extent with geranylgeranyl side chains as a soluble 
transport factor (Zhang, 2004).  
PDEδ was shown to act as a solubilization factor for KRas molecules as well as 
for depalmitoylated isoforms (Chandra, 2012). In fact, PDEδ does not extract 
proteins from membranes rather it passively sequesters farnesylated cargo from 
endomembranes. The presence of PDEδ is essential to counter the entropic 
tendency of farnesylated Ras proteins to randomly distribute to all 
endomembranes (Schmick, 2014a; Schmick, 2015). By facilitating diffusion of 
Ras proteins in the cytoplasm, the kinetics of being enriched at a different 
perinuclear compartments are elevated. If HRas or NRas are solubilized by 
PDEδ, the probability of these farnesylated but depalmitoylated proteins being 
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trapped at the Golgi apparatus is high, due to their higher mobility in complex 
with PDEδ and local PAT activity (Rocks, 2005). In case of KRas, an enrich-
ment at the recycling endosome and the plasma membrane is maintained 
(Schmick, 2015). 
Another interaction partner of PDEδ is the farnesylated protein RheB (Ras 
homolog enriched in brain) (Hanzal-Bayer, 2002; Chandra, 2012; Schmick, 
2014), a regulator of the mammalian target of rapamycin (mTOR). RheB is ac-
tive on lysosomes to recruit mTOR via Rag GTPases, facilitating formation of 
the mTOR complex 1 (mTORC1), which couples information about the availabil-
ity amino acid to cell growth and autophagy. The mTORC1 activity is regulated 
by various input signals, such as growth factors, stress, energy status and ami-
no acids (Sancak, 2008; Sancak, 2010; Jewell, 2013). In contrast to the Ras 
isoforms, RheB lacks an additional reversible palmitoylation and has no polyba-
sic sequence. In this way, it is not trapped at a specific membrane compart-
ment. 
Beside the binding to Ras family members, PDEδ binds to truncated, non-
modified Arl2 and Arl3 (Arf-like GTPase 2/3) proteins in a GTP-specific manner 
(Linari, 1999; Hanzal-Bayer , 2002; Ismail, 2011). In this way, PDEδ is an Arl 
effector, which has a higher affinity for the GTP-bound form of Arl2 and Arl3 
(Hanzal-Bayer, 2002). The complex of Arl2:PDEδ shows typical GNBP:effector 
interactions (guanine nucleotide binding proteins), characteristic for the GTP 
conformation (Hanzal-Bayer, 2005; Hanzal-Bayer, 2002). The PDEδ-Arl2 inter-
action exclusively occurs in the perinuclear area and is strictly GTP-dependent, 
as only Arl2-GTP facilitates release of farnesylated cargo bound to PDEδ. It is 
still unresolved how the locally regulated nucleotide exchange on Arl2 is per-
formed and if unknown GEFs are involved (Schmick, 2015). In summary, PDEδ 
is able to bind Ras, RheB, and other farnesylated proteins functioning as a 
solubilization factor in the cytoplasm and it interacts with Arl2-GTP in the 
perinuclear area to release its cargo, which is subsequently enriched at target 
membranes. In order to understand these functions and properties in more de-
tail, the concept of protein cycles and localized release will be discussed in the 
following chapter. 
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3.5 The PDEδ-Arl2 delivery system serves many clients 
It is already known, that the tight interplay between PDEδ-mediated 
solubilization of farnesylated Ras isoforms and Arl2-GTP-dependent localized 
release in the perinuclear area is inevitable to counter equilibration of Ras to all 
endomembranes (Schmick, 2015).  
As described above, the hypervariable region (HVR) determines the localization 
of Ras proteins due to the respective posttranslational modification. Instead of 
the other isoforms, KRas is only irreversibly farnesylated but utilizes a polybasic 
stretch consisting of eight positively charged lysine residue in the hypervariable 
region. Electrostatic interactions between the negatively charged phospholipids 
at the inner leaflet of the plasma membrane and the lysine residues enhance 
the association of KRas to the plasma membrane (Hancock, 1990; Crouthamel, 
2008; Quatela, 2008). Besides the plasma membrane, the positive charge al-
lows additional intracellular electrostatic interactions with the negatively charged 
membranes of the recycling endosome compartment (Schmick, 2015).  
Although, the combination of farnesylation and electrostatic interactions main-
tains KRas at the plasma membrane, vesicular internalization of the plasma 
membrane by endocytosis, phagocytosis, and pinocytosis constantly occurs. As 
the rate of plasma membrane vesiculation is five times higher than spontaneous 
dissociation of KRas from membranes, the fraction of KRas at the plasma 
membrane is constantly depleted (Schmick, 2014a). Internalized membrane 
loses its asymmetric charge due to the curvature of the formed vesicles. Endo-
cytosis causes a positive curvature on the intracellular and a negative curvature 
on the extracellular leaflet of the plasma membrane, resulting in an equalized 
overall charge (Bohdanowicz, 2013). In this way, the electrostatic interactions 
between KRas and the lipid bilayer no longer exist and KRas can freely diffuse 
in the cytosol until it reaches membranes to associate with. The binding to 
endomembranes is highly dynamic and does not require additional targeting 
signals. Hence, KRas undergoes spontaneous intermembrane transfer via its 
soluble fraction (“hopping”) and equilibrates to all endomembranes with time 
due to a longer dwell time and the extensive surface area of the 
endomembranes system compared to the plasma membrane (Schmick, 2015).  
As mentioned before, the solubilization factor PDEδ is important to sequester 
loosely bound KRas from endomembranes. The binding of KRas to PDEδ en-
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hances its diffusion speed in the cytosol and leads to a faster depletion from 
endomembranes (Schmick, 2014a). Ectopic PDEδ expression was shown to 
reinstate the plasma membrane localization of Ras proteins in HepG2 cells, 
which lack endogenous PDEδ (Chandra, 2012), supporting results from PDEδ 
knockout and inhibitor studies, which demonstrated that the presence of PDEδ 
is essential to maintain KRas enrichment at the plasma membrane (Chandra, 
2012; Zimmerman, 2013). Nonetheless, reaction diffusion simulations clearly 
demonstrate that PDEδ is indeed necessary but not sufficient to localize KRas 
at the plasma membrane (Schmick, 2014a). 
In this way, neither the presence of the polybasic stretch nor PDEδ-mediated 
solubilization and not even a combination of both is sufficient to maintain KRas 
at the plasma membrane. As a consequence, KRas enrichment at the plasma 
membrane is not possible at thermodynamic equilibrium. Therefore, the enrich-
ment at the plasma membrane has to be actively maintained by an energy-
driven mechanism, which involves PDEδ and Arl2-mediated release in the 
perinuclear area (Schmick, 2014a; Schmick, 2015). 
Farnesylated KRas in complex with PDEδ is released in the perinuclear area by 
local Arl2 activity. The interaction between PDEδ and the G-protein Arl2/3 (Is-
mail, 2011) leads to a GTP-dependent release of farnesylated cargo, which can 
then either be rebound by free PDEδ or associate with endomembranes. The 
presence of Arl2-GTP increases the dissociation rate of KRas 10-fold (Ismail, 
2011). As verified by reaction diffusion simulations, the absence of perinuclear 
release causes KRas distribution to all endomembranes. Moreover, KRas has 
an increased probability of getting trapped at Rab11-positive endosomes 
(pericentriolar recycling endosome) (Schmick, 2015). Rab11 is a protein, which 
resides at the recycling endosome, a cellular compartment with negatively 
charged membranes, creating an environment similar to the plasma membrane 
but in close proximity to the nucleus. The presence of the polybasic stretch 
causes an elevated residence time of KRas on the recycling endosome, as 
charged membranes are electrostatically favored compared to endomembranes 
(Schmick, 2014a). Therefore, the dissociation rate of KRas from the recycling 
endosome is low. Hence, it traps and concentrates KRas, which is released 
from the PDEδ-Arl2 complex into the perinuclear space and ensures its directed 
vesicular transport to the plasma membrane (figure 8). 
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Figure 8: Spatial organization of KRas; Due to its polybasic motif in the HVR, KRas localizes to the 
negatively charged inner leaflet at the plasma membrane where it transmits signals from extracel-
lular input inside the cell. Farnesylated KRas has the general tendency to bind to all 
endomembranes. In order to maintain an out of equilibrium distribution, PDEδ sequesters KRas 
from endomembranes and increases solubility in the cytoplasm. Farnesylated cargo bound to 
PDEδ is released in the perinuclear area by Arl2-GTP. Released KRas is either trapped on 
endomembranes or at the recycling endosome (RE) by electrostatic interactions. It is then trans-
ported back to the plasma membrane by directed vesicular transport. 
 
This spatial asymmetry in the distribution of palmitoylated and depalmitoylated 
HRas and NRas is maintained by an acylation cycle (figure 9), which counter-
acts protein leakage from the plasma membrane into endomembranes by en-
docytosis, or fission, or by slow dissociation (Rocks, 2005; Goodwin, 2005). 
HRas and NRas are irreversibly farnesylated and reversibly palmitoylated. They 
localize to the plasma membrane and the Golgi apparatus, respectively. The 
compartmentalization of Ras signaling causes distinct cellular responses with 
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high specificity and the ability to act on multiple signal propagation pathways 
(Lorentzen, 2010). 
Three cooperating factors counter the entropy-driven dilution of these Ras 
isoforms to all membranes to maintain an out-of-equilibrium distribution. First, 
iterative depalmitoylation and repalmitoylation cycles continuously occur, facili-
tated by local palmitoyltransferases (PATs) and cytosolic acyl protein 
thioesterases (APTs) (Vartak, 2014). Upon cleavage of palmitoyl groups by 
thioesterases, the plasma membrane affinity is reduced, concomitant with an 
increased effective diffusion in the cytoplasm. Although the molecules are irre-
versibly farnesylated and they tend to populate endomembranes, their effective 
diffusion speed is high. This is achieved by PDEδ, which binds to farnesylated 
proteins and shields the hydrophobic tail from the cytoplasm, facilitating faster 
diffusion and the PDEδ-Arl2 systems enhances enrichment on target mem-
branes close to the perimuclear area as described for KRas (Schmick, 2014a, 
Schmick, 2015). 
Second, local PAT (palmitoyltransferase) activity traps farnesylated Ras at the 
Golgi surface, thereby generating a higher membrane affinity and a localized 
slower diffusion, concomitant with an elevated residence time (Rocks, 2005). As 
mentioned above, an additional regulation of the amount of solubilized Ras is 
facilitated by the interaction between PDEδ and the G-protein Arl2 (Ismail, 
2011). In its GTP-bound state, Arl2 releases cargo from PDEδ in the perinuclear 
area, which can then either be rebound by free PDEδ or associate with 
endomembranes or directly attach to the Golgi membranes for repalmitoylation 
(Schmick, 2015). 
Third, such kinetically trapped and palmitoylated proteins are unidirectionally 
transported via the secretory pathway from the Golgi apparatus to the plasma 
membrane where they can be activated, completing the acylation cycle (Rocks, 
2005; Rocks, 2010). 
In contrast to doubly palmitoylated HRas, the overall palmitoylation of NRas is 
less stable as it has only one reversible modification. NRas dissociates faster 
from the plasma membrane due to ubiquitous APT activity and gets lost on 
endomembranes (Rocks, 2010; Schmick, 2015). Additionally, thioesterases 
catalyze depalmitoylation of NRas on secretory vesicles. Hence, that fraction of 
NRas originally targeted to the plasma membrane does not reach its destination 
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and is again solubilized by PDEδ, likely to get retrapped at the Golgi apparatus. 
NRas has a lower membrane affinity and palmitate stability, resulting in a more 
pronounced steady-state Golgi localization when compared to HRas (Rocks, 
2010). The palmitoylation pattern together with the ubiquitous APT activity and 
the localized PAT activity cause the different kinetics of HRas and NRas in the 
acylation cycle. 
 
 
Figure 9: Spatial organization of NRas; NRas is farnesylated and palmitoylated at the plasma mem-
brane, palmitoyl moieties are removed by cytosolic thioesterases (APT). Farnesylated NRas is 
solubilized by PDEδ and trapped at the Golgi apparatus for repalmitoylation, catalyzed by local 
palmitoyltransferases (PAT). Palmitoylated NRas is directed to the plasma membrane by vesicular 
transport. Arl2-GTP activity in the perinuclear area facilitates release of farnesylated NRas bound 
to PDEδ. 
 
Besides HRas, NRas, and KRas, the PDEδ-Arl2 complex also interacts with the 
farnesylated Ras-family member RheB (Ras homolog enriched in brain) in the 
perinuclear area (figure 10). In contrast to the Ras isoforms, RheB is only 
farnesylated and has no other modifications or features, which would target it to 
a certain membrane compartment and lower its membrane dissociation. It re-
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mains concentrated on perinuclear membranes and the weak association with 
membranes causes a stronger partitioning into the cytosol (Schmick, 2015). 
Due to the lack of any trapping membrane compartment, RheB equilibrates 
faster from these perinuclear membranes to the huge endomembrane surface 
(Schmick, 2015). 
 
 
Figure 10: The displacement of farnesylated cargo from the PDEδ-Arl2 system in the perinuclear 
area is responsible for KRas (left) and HRas (middle) enrichment at the plasma membrane. RheB 
(right) is another client of the delivery system and enriches in the perinuclear area. With time, it 
rapidly equilibrates to endomembranes as it lacks an additional feature for trapping it at a vesicular 
transport compartment. Figure adapted from Schmick et al., 2015. 
 
In this way, the PDEδ-Arl2 delivery system is the main driver for the different 
spatial localizations of HRas, NRas, KRas and RheB, facilitating trapping at the 
right membrane compartment. The release of farnesylated cargo on perinuclear 
membranes instead of delivery at the plasma membrane is a common mecha-
nism in all cycles (figure 10). For Ras, its subsequent enrichment on a specific 
trapping compartments and the directed transport to the plasma membrane 
counter the equilibration to endomembranes. For RheB, the leakiness of 
perinuclear membranes causes an equal distribution to endomembranes.  
 
3.6 PDEδ inhibition causes KRas delocalization 
The importance of PDEδ in maintaining the spatial organization of Ras family 
proteins and convincing results from knockout studies (Chandra, 2012), de-
manded for the development of small molecule PDEδ inhibitors. 
In 2013, a highly potent PDEδinhibitor (KD < 5 nm), Deltarasin, was published 
to have an impact on KRas-dependent cells by interference with the spatial or-
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ganization of KRas. Deltarasin has a benzimidazole-based lead structure and 
was the first inhibitor found to specifically bind to PDEδ thereby indirectly target-
ing oncogenic KRas-dependent growth and signaling by depleting KRas from 
the plasma membrane. This inhibitor mimics a farnesyl moiety and binds to the 
farnesyl-binding pocket of PDEδ with high affinity thereby affecting the localiza-
tion and Ras-induced proliferative information, transmitted via the MAPK path-
way (Zimmermann, 2013). 
Upon PDEδ inhibition, KRas cannot compete with the drug bound to the hydro-
phobic pocket and is therefore not solubilized in the cytoplasm. With time, the 
fraction of KRas at the plasma membrane decreases and the spatial organiza-
tion is disrupted as PDEδ is essential to maintain the out-of-equilibrium distribu-
tion and KRas gets enriched on endomembranes (figure 11). 
 
 
Figure 11: Schematic representation of the KRas cycle in the presence of Deltarasin. The farnesyl-
binding pocket is blocked by Deltarasin and PDEδ is incapable to solubilize KRas. KRas populates 
all endomembranes and the fraction at the plasma membrane decreases with time. Deltarasin can 
be released in the perinuclear area by Arl-2, hence a higher effective inhibitor concentration is 
inevitable to rebind to the hydrophobic pocket to stop the KRas cycle. 
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For Deltarasin, an ‘in cell’ KD of 41 ± 12 nM was calculated from dose-response 
data acquired with FLIM, demonstrating its high affinity. Moreover, experiments 
in human pancreatic cancer cells, as KRas is regularly mutated in such tumors, 
demonstrate that PDEδ inhibition causes death in KRas-dependent cell lines 
but not in KRas-independent cell lines (Zimmermann, 2013).  
One year later, a second compound, named Deltazinone 1 was found to bind to 
PDEδ with very low nanomolar affinity (KD < 5 nm). Deltazinone 1 is based on a 
pyrazolopyridazinone scaffold and exhibits an ‘in cell’ KD of 58 ± 17 nM (Papke, 
2015). Both inhibitors mimic farnesylated proteins and bind to the hydrophobic 
binding pocket of PDEδ in the same manner and with high affinities at 
nanomolar concentrations. Figure 12 shows the formation of hydrogen bonds 
between Deltarasin and three residues (Y149, R61, and C56) of the PDEδ bind-
ing pocket (Zimmermann, 2013). 
 
Figure 12: Binding mode of Deltarasin to PDEδ. The molecular docking proves the existence of 
three hydrogen bonds between Deltarasin and the hydrophobic binding pocket of PDEδ. The 
piperidine moiety interacts with the backbone carbonyl of cysteine 56 and the benzimodazole units 
with arginine 61 and tyrosine 149. Figure adapted from Zimmermann et al., 2013. 
 
In order to validate PDEδ as a suitable target, genetic downmodulation with 
doxycycline-inducible shRNA against PDEδ was already performed in pancreat-
ic cancer cell lines. The data corroborates the growth inhibitory effects after in-
hibitor treatment in KRas-dependent cells.  
In this way, it is promising to further study and compare the effects of genetic 
downmodulation and small molecule PDEδ inhibition on a larger panel of differ-
ent cancer cells with known dependencies on oncogenic KRas. In this work, I 
was particularly interested to further explore the relationship between PDEδ and 
the KRas status in different settings and to emphasize possible strategies for 
targeted cancer therapy. 
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3.7 Genetic validation of PDEδ in human cancer cells 
It was already proven in 2013, that RNAi-mediated downmodulation of PDEδ 
leads to death in KRas-dependent but not in KRas-independent human PDACs 
(Zimmermann, 2013). 
For the experimental design of this work, a panel of human cancer cell lines 
lines from pancreatic, colorectal, lung, and cervix carcinomas were chosen for 
genetic manipulation of PDEδ by doxycycline-inducible shRNA. These cell lines 
were selected due to their known KRas status (Singh, 2009; Babij, 2011; Singh, 
2012) and are listed in table 1. They are a representative panel in terms of re-
sponse and tumor origin, as these cancers are all known to gain oncogenic 
KRas mutations with time. 
The PDAC cells Panc-TuI, Panc-1, Capan-1 and BxPC-3 were already shown 
to have a KRas-dependent growth behavior after PDEδ depletion (Zimmer-
mann, 2013). The cell lines HCT-116 and Hke-3 are isogenic in the way that 
oncogenic KRas was depleted by homologous recombination in HCT-116 to 
become Hke-3. In this way, they represent an ideal system to study oncogenic 
KRas dependency. The cell line HT-29 harbors an oncogenic BRaf mutation 
and has a KRast wildtype background. As BRaf functions downstream of KRas, 
such mutant cell lines are not likely to gain an additional KRas-dependency. 
 
Table 1: Human cell lines subjected to RNAi-mediated PDEδ downregulation with known KRas 
dependencies. Pancreatic cancer cell lines are depicted in red. Colorectal carcinoma cells are 
shown in blue and lung cancer cell lines are shown in green. A431 is a cervix carcinoma cell line 
with overexpressed EGFR and colored in black. (1 = Singh, 2009, 2 = Singh, 2012) (3 = Babij, 2011) 
 
KRas depend-
ent 
KRas dependen-
cy (border ) 
KRas independ-
ent 
KRas wild-type 
unknown KRas 
dependency  
Panc-TUI 
1
 HCT-116 
2
 Panc-1 
1,3
 BxPC-3 
3
 SW480 (KRas mut) 
Capan-1 
1,3
 
 
A549 
1
 
HT-29 
3
 (BRaf 
V600E)  
MIAPaCa-2 
3
 
  
Hke3 
2
 
 
H358 
1
 
  
A431 (EGFR 
overexpr.)  
H441 
1
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The idea is, that genetically inducible downmodulation of PDEδ mirrors the ef-
fect of specific inhibitors without unwanted side effects. It was already shown, 
that siRNA against PDEδ causes a delocalization of Ras from the plasma 
membrane to endomembranes (Chandra, 2012). In this way, the depletion of 
endogenous PDEδ leads to an interference with the spatial organization of Ras, 
by causing a random distribution to all endomembranes and diminishing the 
plasma membrane fraction. In order to correlate the effects of PDEδ knockdown 
with the respective KRas status, all cell lines were subjected to proliferation 
studies after stable shRNA insertion in the presence and absence of doxycy-
cline. Further, the growth behavior of genetically modified cells was compared 
to small molecule inhibition by either Deltarasin or Deltazinone 1. 
 
3.8 The mPDAC model system 
Apart from the subset of human cancer cell lines with different tumor origins and 
heterogenious protein expression patterns, murine pancreatic ductal adenocar-
cinoma cells were also subjected to small molecule inhibition of PDEδ. They 
were designed to express oncogenes under control of endogenous promoters, 
using Cre-Lox technology (Hingorani, 2003; Tuveson, 2005; Hingorani, 2005) 
These mouse models clearly demonstrated that conditional activation of onco-
genic KRas via Pdx1 (pancreatic progenitor cell gene promoter) leads to neo-
plasm formation, similar to the human disease (PanINs) (Tuveson, 2005). As 
such, they are a defined, homogenous, and characterized system to study 
PDAC (pancreatic ductal adenocarcinoma), allowing for studies on basic regula-
tory mechanisms of the MAPK pathway in an oncogenic KRas environment. 
In this project, mPDAC (murine pancreatic ductal adenocarcinoma) cells, with 
either a single oncogenic KRas G12D knock-in (KRasG12D(-/+), KC, single knock-
in, single mutant) or with KRasG12D(-/+) and p53R270H(-/+) (KPC, double knock-in, 
double mutant), a contact mutant, which tends to accumulate, were used. Only 
mice with mutant gain-of-function p53 develop pancreatic cancer metastasis, in 
contrast to p53 knockout animals (Morton, 2010). The single mutant (mPDAC 
79990, KRasG12D(-/+), KC) represents early stage PDAC, whereas the double 
mutant (mPDAC 79751, KRasG12D(-/+) and p53R270H(-/+), KPC) mimics late stage 
PDAC progression in humans (Olive, 2004; Hezel, 2006).  
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4 Objectives 
How are human cancer cells from different tumor origins affected by the in-
duced downmodulation of PDEδ? Is there a correlation between the availability 
of PDEδ and the KRas mutation status? Are there differences in KRas-
dependent and -independent cell lines after PDEδ knockdown or inhibition? Is 
PDEδ a valid target to inhibit oncogenic KRas-dependent signaling and does it 
affect downstream signaling (MAPK-pathway)? 
 
Is there a correlation between the p53 status and the resistance towards PDEδ 
inhibition? Is the knock-in of oncogenes and/or corrupt tumor suppressor genes 
sufficient to change the network behavior and to drive oncogene addic-
tion/synthetic lethality? 
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5 Results 
5.1 Generation and characterization of stably trans-
formed human cancer cell lines  
The panel of human cell lines (table 1) was lentivirally transduced to stably ex-
press doxycycline-inducible shRNA against PDEδ and selected with puromycin 
(see M&M). In order to determine the time-point of efficient PDEδ 
downmodulation, all cell lines were treated with doxycycline for up to 3 days. 
Efficient PDEδ downmodulation was observed after 72 h doxycycline induction 
in all cell lines, shown in figure 13 for Panc-TUI cells as a representative exam-
ple. PDEδ was already described to be a stable protein (Chandra, 2012), which 
requires several days of RNAi-treatment to see changes in the protein level. In 
general, the knockdown level was proven to be time-dependent and further ex-
periments were carried out after 72 h doxycycline treatment.  
 
 
Figure 13: Western Blot analysis of PDEδ downmodulation by doxycycline induction for Panc-TUI 
cells. Blots were stained for PDEδ and Cyclophilin B (loading control). With different doxycycline 
incubation times as indicated, a time-dependent downmodulation of PDEδ was visible. An efficient 
downmodulation could be observed after 72 h doxycycline incubation. The induction was carried 
out with 0.2 µg/ml doxycycline. 
 
To evaluate the level of PDEδ downmodulation in all previously mentioned hu-
man cancer cell lines, Western Blots were carried out with a constant amount of 
total protein, determined by Bradford assay, in lysates from cells before and 
after doxycycline induction (figure 14). 
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Figure 14: PDEδ and CyclophilinB (loading control) levels shown by Western Blot for each stably 
transduced cell line. The human PDAC cells are shown on top .Capan-1* cells were selected with 
higher puromycine concentrations (4 µg/ml). The CRC, lung, and cervix carcinoma cells are shown 
below. Doxycycline was incubated for 72 h prior to cell lysis and subsequent SDS PAGE. A total 
protein concentration of 50 µg was loaded for each protein sample.  
 
All stably transfected cell lines responded to doxycycline as the endogenous 
PDEδ levels were mostly depleted when compared to the corresponding un-
treated sample (figure 14). This proves that the shRNA was sucessfuly inserted 
and functioning after doxycycline incubation. This is corroborated by the fact, 
that control cell lines with stably expressed scrambled shRNA showed no effect 
on PDEδ after doxycycline addition, as demonstrated by Panc-TuI and HT-29 
cells in figure 15. 
 
Figure 15: PDEδ and CyclophilinB (loading control) levels shown for scrambled shRNA and shRNA 
against PDEδ by Western Blot for Panc-TuI and HT-29 cells. Doxycycline was incubated for 72 h in 
both conditions. A clear decrease in the PDEδ level was only observed with the targeting shRNA 
but not with scrambled shRNA. 
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When comparing the basal amount of PDEδ in all cell lines, MIA PaCa-2, HCT-
116, and A431 cells exhibited increased levels, whereas BxPC-3 and HT-29 
cells showed lower band intensities (figure 14). MIA PaCa-2 and HCT-116 cells 
were reported to be oncogenic KRas-dependent and BxPC-3 and HT-29 are 
KRas wild-type cells. Solely, the Capan-1 cell line showed the highest level of 
remaining PDEδ protein after 72 h doxycycline treatment even with higher se-
lection pressure (Capan-1*). Another interesting observation is, that HCT-116 
and Hke-3 cells, which are isogenic exhibit different levels of endogenous 
PDEδ. HCT-116 cells are KRas dependent and have elevated PDEδ levels as 
compared to Hke-3 cells, pointing towards a connection between the KRas mu-
tation status and the amount of PDEδ inside the cell. 
To further quantify the endogenous amount of PDEδ in all cell lines, information 
can be inferred by using a calibration curve with known concentration of purified 
PDEδ. Again, the lowest endogenous amount of 2-25 ng was measured in 
BxPC-3 and HT-29 cells, which are KRas-independent. HCT-116 cells exhibited 
overall the highest level of endogenous protein (200 ng) and in the remaining 
cell lines the amount was between 50-100 ng. The isogenic cell line Hke-3 was 
also confirmed to have high levels of PDEδ but still less than HCT-116 cells 
(figure 16). 
In general, the amount of endogenous PDEδ was lower in KRas-independent 
(wild-type) cells and this might correlate with the susceptibility towards 
downmodulation of PDEδ. As the wild-type cell lines BxPC-3 and HT-29 are not 
KRas-dependent, they might require lower basal PDEδ levels and tolerate the 
knockdown, as seen with HCT-116 and Hke-3. Further, yet unknown 
solubilization factors might compensate the role of PDEδ in these cell lines. 
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Figure 16: Calibrated PDEδ-levels of the human cancer cell lines shown in figure 14. A calibration 
curve was derived from a dilution series of purified PDEδ protein and used to determine the en-
dogenous PDEδ concentration in all cell lines. 
 
5.2 Inducible RNAi has an effect on cell proliferation in 
human cancer cell lines 
As Deltarasin was published to have a dose-dependent growth inhibitory effect 
on oncogenic KRas dependent human PDACs (Zimmermann, 2013), all cell 
lines were subjected to real-time cell proliferation measurements, monitored by 
RTCA (real-time cell analyzer). For this, 10,000 cells were plated in each well of 
a 16-well E-plate and half of the samples were grown under doxycycline condi-
tions to start PDEδ downmodulation. The red curves represent the change in 
the Cell Index (A.U.) with time in presence of doxycycline and the black curves 
represent the control measurements of the same cell line without doxycycline 
addition (figure 17). 
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Figure 17: RTCA measurements of human pancreatic cancer cell lines. The oncogenic KRas-
independent cell lines Panc-1, the KRas wild-type cell line BxPC-3 and the oncogenic KRas-
dependent Panc-TuI cells are shown on top. The cell lines from Bochum (MIA PaCa-2 and Capan-1) 
are shown below. Dr. B. Papke performed the RTCA measurements for the Capan-1 cells. The ef-
fect of doxycycline-induced PDEδ knockdown is shown for each cell line, where the black curve 
represents cells under serum conditions and the red curve cells in the presence of 0.2 µg/ml 
doxycycline. Doxycycline was initially added. 
 
The oncogenic KRas-dependent cell lines Panc-TuI and MIA PaCa-2 exhibited 
strong growth inhibitory effects after doxycycline-induced downmodulation of 
PDEδ, as shown by the red graph (figure 17). Interestingly, the KRas wild-type 
bearing BxPC-3 cells also changed the growth behavior after PDEδ knockdown. 
The oncogenic KRas-independent Panc-1 cells exhibited minor growth effects.  
 
Second, the human colorectal cancer cell lines HCT-116, Hke-3, HT-29, and 
SW 480 were used to validate possible growth inhibitory responses by RTCA 
(figure 18). As aforementioned, the red curves represent the presence and the 
black curves the absence of doxycycline. 
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Figure 18: RTCA measurements in human colorectal carcinoma cells in the presence of doxycy-
cline-inducible shRNA against PDEδ. The effect of doxycycline-induced PDEδ knockdown is 
shown for each cell line, where the black curve represents cells under serum conditions and the 
red curve cells in the presence of 0.2 µg/ml doxycycline. Doxycycline was added after 24 h. 
 
 
In case of all human CRC cells, no major effect of PDEδ downregulation on pro-
liferation could be observed. The black and red graphs overlapped, indicating 
no effect on the Cell Index. Solely, the HCT-116 cell line displayed a slight ten-
dency towards PDEδ-mediated growth effects at later time points (figure 18). 
HCT-116 harbors oncogenic KRas. As discussed before, HCT-116 and Hke-3 
cells are isogenic, where mutant KRas was deleted by homologous recombina-
tion in the latter. Accordingly, Hke-3 cells were defined as KRas wild-type cells 
(Singh, 2012) and unlikely to respond to PDEδ inhibition. The small difference in 
their proliferation could therefore point towards an effect of oncogenic KRas. 
The Western Blot data support the fact that any effect on growth obtained by 
RTCA is exclusively caused by varying amounts of PDEδ. 
HT-29 cells were reported to have wild-type KRas in combination with an addi-
tional BRaf (V600E) mutation, which functions downstream of KRas and causes 
resistance to certain chemotherapeutics (Di Nicolantonio, 2008). Moreover, this 
cell line clearly showed low endogenous PDEδ levels, determined by Western 
Blot and its proliferation seems to be unaffected by PDEδ downmodulation. 
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Finally, the human lung cancer cell lines A549, H441, and H358 and the cervix 
carcinoma cell line A431 were selected for transduction with inducible shRNA 
against PDEδ. Unfortunately, H441 and H358 cells did not tolerate viral infec-
tion and underwent apoptosis during further maintenance within 2 weeks. In 
summary, 2 out of these 4 cell lines could be generated to stably express PDEδ 
shRNA. Only the oncogenic KRas-dependent H358 cell line could be used for a 
single RTCA measurement (figure 19) but not further due to a complete loss of 
cultured cells within days. Nonetheless, the effect on the cell growth after 
doxycycline application was clearly visible, as these cells are known to be de-
pendent on the KRas oncogene. 
 
 
Figure 19: RTCA measurements of the human lung cancer cell line H358 in the presence of 
doxycycline-inducible shRNA against PDEδ. The black curve represents cells under serum condi-
tions and the red curve cells in the presence of doxycycline. Doxycycline was added after 24 h. 
 
To validate possible growth inhibitory responses in the cervical cancer cell line 
A431 and in A459 lung cancer cells after doxycycline addition, they were moni-
tored by RTCA (figure 20). 
From the data it could be concluded that these cell lines responded to PDEδ 
downmodulation, as visualized by growth effects at later time points (figure 20). 
Although A459 cells are classified to be KRas-independent, a clear difference 
after PDEδ depletion was observed. A431 cells are characterized by overex-
pressed EGFR. As Ras is a downstream integrator for EGFR signaling, prolifer-
ative signaling via Ras might be affected by PDEδ downmodulation in these 
cells. 
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Figure 20: RTCA measurements in human lung (left) and cervix carcinoma cells (right) in the pres-
ence of doxycycline-inducible shRNA against PDEδ. The effect of doxycycline-induced PDEδ 
knockdown is shown for each cell line, where the black curve represents cells under serum condi-
tions and the red curve cells in the presence of doxycycline. Doxycycline was added at the begin-
ning of the experiment. 
 
 
5.3 Comparison between small molecule inhibition and 
RNAi in human cancer cell lines 
As mentioned before, the idea was to compare data from the genetic validation 
of PDEδ with small molecule PDEδ inhibition. The genetic approach ideally rep-
resents chemical PDEδ inhibition without side effects. To allow for a clear corre-
lation between PDEδ depletion and genetic interference, the acquisition of cell 
growth in hPDACs (figure 21) was performed with doxycycline-inducible shRNA 
and compared to varying inhibitor concentrations of Deltarasin and 
Deltazinone 1 (inhibitor data generated by Holger Vogel). 
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Figure 21: RTCA measurements of human pancreatic cancer cell lines. The effect of doxycycline-
induced PDEδ knockdown is depicted on the left. The black curve represents cells under serum 
conditions and the red curve the addition of doxycycline. Doxycycline was initially added. The 
respective PDEδ protein levels in the presence or absence of doxycycline (72 h) are determined by 
Western blots. The dose-dependent effects on growth caused by Deltazinone 1 (middle panel) and 
Deltarasin (left panel) are shown (data acquired by Holger Vogel). Both PDEδ inhibitors were added 
at the indicated time points (arrow) in the respective concentrations. For b and c, the cell indices 
were normalized to the time of drug addition. Data for Capan-1 cells, including Weatern Blot and 
RTCA were generated by Dr. B. Papke. Figure adapted from Papke et al., 2015. 
 
Again, the strongest effects on cell growth could be measured in KRas-
dependent cell lines (Panc-TuI, MiaPaCa-2, Capan-1). The KRas-independent 
Panc-1 cells showed no significant reduction in growth, neither with shRNA nor 
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Deltazinone 1. Only the BxPC-3 cell line, which is classified to be KRas-
independent, displayed a stronger reduction in growth with shRNA when com-
pared to Deltazinone 1. With Deltarasin, a dose-dependent cell death was 
measured in all cell lines. 
The comparison between shRNA-mediated PDEδ downmodulation and the two 
PDEδ inhibitors was also extended to CRC (figure 22) and lung cancer cells 
(figure 23) 
 
 
Figure 22: RTCA measurements of human colon rectal carcinoma cell lines. The effect of doxycy-
cline-induced PDEδ knockdown is depicted on the left, where the black curve represents cells 
under serum conditions and the red curve cells in the presence of doxycycline. Doxycycline was 
added after 24 h. The dose-dependent effects on growth caused by Deltazinone 1 (middle panel) 
and Deltarasin (left panel) are shown (data acquired by Holger Vogel). Both PDEδ inhibitors were 
added at the indicated time points (arrow) in the respective concentrations. For b and c, the cell 
indices were normalized to the time of drug application. 
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As expected, the CRC cell lines showed little, in case of HCT-116 cells, or no 
response to PDEδ downmodulation (figure 22, left). HCT-116 cells are on the 
border to KRas-dependency, whereas all other CRC cell lines are published to 
be KRas-independent. The isogenic cell lines HCT-116 and Hke-3 showed a 
similar growth behavior when treated with Deltzinone 1 and Deltarasin, respec-
tively. The oncogenic BRaf mutation in HT-29 cells seems to also cause re-
sistance to chemical PDEδ inhibition. Here, no effect of Deltazinone 1 could be 
observed, even at higher concentrations. As observed for hPDACs, Deltarasin 
causes cell death at higher doses in all cell lines with time. 
The lung cancer cell lines A549 and A358 were also compared to Deltazinone 1 
and Deltarasin (figure 23). 
Unfortunately, no further data than a single RTCA measurement could be per-
formed with the oncogenic KRas-dependent lung cancer cell line H358. Never-
theless, a clear effect on growth could be measured, as it was expected and 
which is mirrored in the presence of Deltazinone 1. A549 cells only showed a 
slight reduction in proliferation with Deltazinone 1. 
 
 
Figure 23: RTCA measurements of human lung cancer cell lines. The effect of doxycycline-induced 
PDEδ knockdown is depicted on the left, where the black curve represents cells under serum con-
ditions and the red curve cells in the presence of doxycycline. Doxycycline was added after 24 h. 
The dose-dependent effects on growth caused by Deltazinone 1 (middle panel) and Deltarasin (left 
panel) are shown (data acquired by Holger Vogel). Both PDEδ inhibitors were added at the indicat-
ed time points (arrow) in the respective concentrations. For b and c, the cell indices were normal-
ized to the time of drug application. 
 
In summary, the impedance-based measurements in the presence of genetic 
PDEδ knockdown highly correlate with those generated in the presence of 
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Deltazinone 1 in all cell lines. Moreover, Deltazinone 1 exhibits higher specificity 
for PDEδ and a broader herapeutic window and less cytotoxicity when com-
pared to Deltarasin. Nonetheless, the general tendency of growth inhibition in 
the presence of Deltarasin is also mirrored by the genetic knockdown. 
From this it can be inferred that the genetic validation proves the importance of 
available PDEδ in oncogenic KRas-dependent cells.  
 
5.4 Clonogenic assays to study long-term effects of 
PDEδ knockdown 
Efficient PDEδ downmodulation by shRNA was achieved after 72 h doxycycline 
treatment in all cell lines, as demonstrated by Western Blots for Panc-TuI cells 
(figure 13). RTCA measurements showed clear growth inhibitory effects in on-
cogenic KRas-dependent hPDACs, slight effects in lung and cervix cancer, but 
not in CRCs. This is corroborated by data with the small molecule inhibitor 
Deltazinone 1. The slight effects on growth at longer time points gave reason for 
the following experimental approach. 
Clonogenic assays with or without doxycycline were performed in triplicates to 
study long-term effects on growth in the stable transfected human cancer sys-
tems (figures 24, 25, 26). For this, sparsely seeded cells (2,000/ well for 
hPDACs and CRC and 1,000/well for A459 and A431) were maintained in a 6-
well plate in the presence or absence of doxycycline for 7-10 days and then 
fixed and stained with crystal violet to visualize individual colonies. The quantifi-
cation was performed on IR-scanned (Licor, Odyssey) images with equal sizes. 
ImageJ was used to track (particle tracking tool) and measure the particles of 
each well to plot their average size, the colony number, and the plate coverage. 
In general, clonogenic assays give information about cytostatic effects, where 
the colony size is reduced when compared to the control condition and about 
cytotoxic effects, which means that colonies vanish with time. In addition to 
clonogenic assays, long-term RTCA measurements were carried out for the 
respective cell lines for 7-10 days. Previous RTCA measurements were carried 
out for only 100-120 h (figures 24, 25, 26). First, all hPDACs were subjected for 
studying long-term effects after PDEδ downmodulation (figure 24). Second, 
long-term growth effects were studied in CRC cell lines (figure 25) and third in 
cervix and lung carcinoma cells (figure 26). 
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Figure 24: Clonogenic assays and the respective quantification of hPDACs after 7-10 days with and 
without doxycycline (left). All cell lines were seeded sparsely at 2,000 cells/well in a 6-well plate 
and incubated with or without doxycycline. The average colony size, the number of colonies and 
the total area in untreated samples is represented by the black bar and the doxycycline conditions 
are shown in red (middle). The respective long-term RTCA measurement (2,000 cells/well) is shown 
on the right, where the black curves represents the serum condition and the red curve the induced 
downmodulation after doxycycline addition. Doxycycline was initially added in all experiments. 
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The quantification of each clonogenic assay in all human PDACs clearly 
showed long-term effects of PDEδ knockdown by RNAi (figure 24). The onco-
genic KRas-dependent Panc-TuI and MIA PaCa-2 cells displayed the strongest 
effects, because no or very few colonies remained when PDEδ was 
downmodulated, indicating that PDEδ is inevitable for their survival (cytotoxici-
ty). The Capan-1 cells, published to be dependent on oncogenic KRas, showed 
only minor effects on the colony size and plate coverage. BxPC-3 cells, which 
also responded to PDEδ downmodulation in RTCA measurements, displayed a 
clear reduction in colony size but not in the total number of colonies. The Kras-
independent Panc-1 cells showed a slight reduction in the colony size (fig-
ure 25, left). Sadly, the quantification regarding the increase in the number of 
colonies, but a decrease in the total area, is not meaningful. This means, that 
for certain cell lines, the particle tracking has to be improved to allow for a more 
representative quantification of the respective image. 
In all long-term RTCA measurements, an RNAi-mediated growth inhibition could 
be demonstrated at later time points. Again, Panc-TUI cells displayed the 
strongest inhibition on cell growth by PDEδ downmodulation and Panc-1 cells 
the lowest. This RTCA data mimicked the growth effects observed by 
clonogenic assays in the presence of PDEδ shRNA. The long-term studies cor-
roborated the results generated by short-term RTCA, which show that KRas-
dependent cells are more susceptible to PDEδ knockdown. Nonetheless, long-
term studies prove an effect of PDEδ RNAi on cell growth in all hPDACs at 
longer time points. 
As aforementioned, clonogenic assays with or without doxycycline were per-
formed to also study long-term effects on growth in the stable transfected hu-
man CRCs (figure 25). 
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Figure 25: Clonogenic assays and the respective quantification of human CRC cell lines after 7-10 
days with and without doxycycline (left). All cell lines were seeded sparsely at 2,000 cells/well in a 
6-well plate and incubated with or without doxycycline. The average colony size, the number of 
colonies and the total area in untreated samples is represented by the black bar and the doxycy-
cline conditions are shown in red (middle). The respective long-term RTCA measurement (2,000 
cells/well) is shown on the right, where the black curves represents the serum condition and the 
red curve the induced downmodulation after doxycycline addition. Doxycycline was initially added 
in all experiments. 
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In 3 of 4 human colon rectal cancer cells, the clonogenic assays showed long-
term effects on growth after PDEδ knockdown by doxycycline-inducible shRNA. 
The mutant KRas-harboring cell line HCT-116 exhibited the strongest reduction 
in colony size, colony number and plate coverage. As discussed for short-term 
RTCA data, Hke-3 and HCT-116 are isogenic cell lines that differ in their KRas 
mutation status, the effect of PDEδ downmodulation was expected to vary. 
HCT-116 cells indeed showed a stronger reduction in growth, as indicated by 
the respective percentage of plate coverage for both cell lines (figure 25). Their 
isogenic counterpart, Hke-3, showed a clear reduction of the colony size, but 
the amount of colonies seemed to be unaffected, which explains a reduction the 
overall plate coverage. SW 480 cells were similarly affected as Hke-3 cells in 
clonogenic assays, but showed a clear time-dependent cell death in long-term 
RTCA measurements. It could be argued that SW480 cells are more suscepti-
ble to nutrient supply, as no medium exchange was performed during RTCA 
measurements. For clonogenic assays, the medium was replaced every three 
days. Hence, in RTCA measurements the additional depletion of nutrients could 
have also influenced cell growth. The mutant BRaf cells HT-29 did not show any 
change in growth, neither when subjected to RTCA measurements nor in 
clonogenic assays, thereby lacking any long-term response. Again, the results 
from long-term studies corroborated the RTCA data and PDEδ downmodulation 
seemed to affect nearly all cell lines on a longer time scale. 
The stable transfected human lung cancer cell line A549 and the cervix carci-
noma cells A431 were also used for clonogenic assays. Cells (1,000 cells /well) 
were incubated for 7-10 days with or without doxycycline to study long-term ef-
fects on growth (figure 26). 
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Figure 26: Clonogenic assays and the respective quantification of lung and cervix cells after 7-10 
days with and without doxycycline (left). All cell lines were seeded sparsely (1,000 cells/well) in a 6-
well plate and 24 h later doxycycline was applied. The average colony size (middle panel) in un-
treated samples is represented by the left bar and the doxycycline conditions are shown on the 
right. The area coverage for each sample is shown in the right panel. Again, the left bar indicates 
growth conditions in the absence and the right bar in the presence of doxycycline. 
 
After doxycycline addition, A459 colonies vanished nearly completely, compa-
rable to the data from oncogenic KRas-dependent hPDACs. The remaining col-
ony spots were hard to resolve with the particle tracking algorithm. Again, fur-
ther improvements are needed to allow for a meaningful representation and 
quantification of long-term data. Nonetheless, the RTCA long-term studies indi-
cated strong effects on colony growth. For the cervix carcinoma cells A431, with 
overexpressed EGFR, a reduced colony size and probably a reduction of the 
total colony size could be visualized in clonogenic assay. This cell line could not 
be monitored by long-term RTCA as these cells are highly proliferative and 
quickly populate RTCA wells, which might also cause nutrition problems as dis-
cussed for SW 480 cells. 
The long-term studies in all human cancer cell lines strongly support the obser-
vation that PDEδ RNAi has long-term effects on cells, predominantly and more 
severe in oncogenic KRas-dependent cancer cells. 
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5.5 Visualization of endogenous Ras by immunofluores-
cence 
So far, it could be inferred from all previous experiments that RNAi-mediated 
knockdown of PDEδ resulted in cell death in KRas-dependent cells and caused 
varying degrees of long-term growth inhibitory effects in all tested cells, except 
for HT-29 cells. To further study the underlying mechanism, which causes cell 
death and if there is spatial interference with KRas by PDEδ inhibition or genetic 
depletion, endogenous Ras staining was performed. For this, Ras was visual-
ized using a primary pan Ras antibody and an Alexa488-labeled secondary an-
tibody in the absence or presence of doxycycline, in combination with Deltarasin 
or Deltazinone 1. The induction of PDEδ shRNA decreases the endogenous 
amounts of PDEδ. By additional application of PDEδ inhibitors, the remaining 
endogenous PDEδ should be inhibited thereby causing a complete 
relocalization of Ras to endomembranes. As discussed before, PDEδ inhibitors 
disrupt KRas and PDEδ binding and thereby the out-of-equilibrium distribution 
of KRas, which should allow to visualize this process. 
Prior to immunostaining, cells were treated for 30 h with doxycycline, as longer 
incubation time might have already killed the cells as observed by RTCA. The 
respective inhibitor was added 2 h before fixation. 
Here, MIA PaCa-2 cells exhibited a strong accumulation of fluorescence in the 
perinuclear area in the presence of doxycycline and Deltarasin but only with 
higher amounts of Deltazinone 1 (20 µM). The combination of doxycycline-
induced downmodulation and Deltarasin seemed to enhance perinuclear Ras 
enrichment (figure 27). MIA PaCa-2 cells are dependent on oncogenic KRas 
and their growth was shown to be affected by genetic downmodulation and 
small molecule inhibition, respectively. Hence, it is likely that the observed ele-
vated fluorescence on endomembranes in this experiment represents the per-
turbed spatial organization of Ras. 
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Figure 27: Immunofluorescence images with a primary anti pan Ras and an Alexa488-labeled sec-
ondary antibody in MIAPaCa-2 cells. Doxycycline was added 30 h before fixation (lower panels). 
Both inhibitors were applied to the respective sample 2 h prior to fixation. 
 
In contrast to MIA PaCa-2 cells, the KRas-independent Panc-1 cells were posi-
tively stained for pan Ras mainly at the cell periphery. This could be observed in 
all conditions, indicating plasma membrane bound Ras. The presence of 
doxycycline showed slightly enhanced perinuclear staining compared to control 
samples (figure 28). The addition of Deltazinone 1 seemed to enhance the fluo-
rescence intensity at the plasma membrane (figure 28). 
The comparison between the two cell lines supported the idea that oncogenic 
KRas-dependent cells seem to be susceptible to interference with the spatial 
organization of Ras. This is corroborated by immunofluorescence images from 
CRC cells, which showed no perinuclear enrichment of fluorescence after PDEδ 
inhibition (data not shown). 
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Figure 28: Immunofluorescence images with a primary anti pan Ras and an Alexa488-labeled sec-
ondary antibody in Panc-1 cells. Doxycycline was added 30 h before fixation (lower panels). Both 
inhibitors were applied to the respective sample 2 h prior to fixation. 
 
5.6 PhosTag-FLIM to determine Erk2 activity in Panc-TuI 
In summary, PDEδ inhibition and RNAi-mediated downmodulation exhibited 
clear effects on growth in mutant KRas-dependent cells and endogenous Ras 
delocalization to endomembranes was determined by immunofluorescence. As 
already mentioned in the beginning, the presence of oncogenic KRas likely en-
hances MAPK signaling. To study possible effects on signaling by PDEδ inhibi-
tion, the following experiment, based on PhosTag-FLIM, was designed to quan-
tify Erk2 phosphorylation under different environmental conditions (DMSO con-
trol, PDEδ inhibitors, and shRNA). For this, mCitrine-Erk2 was transfected in 
Panc-TUI cells, either with 36-48 h doxycycline or 2 h inhibitor incubation prior 
to fixation and subsequent PhosTag-Cy3.5 staining. 
Minimum 4 cells for each set were measured with FLIM and analyzed by global 
data analysis (Grecco, 2010). The average change in the donor lifetime per cell 
and the corresponding mean α value were represented in box plots (figure 31). 
In the presence of FRET, Erk2 is phosphorylated and thereby activated and 
interacts with PhosTag, a phosphor-sensitive probe. The donor fluorophore 
mCitrine was linked to Erk2 and the acceptor fluorophore Cy3.5 was bound to 
PhosTag. 
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Figure 29: PhosTag-FLIM in Panc-TUI cells in the presence and absence of Deltarasin, 
Deltazinone 1, doxycycline, or DMSO. The fluorescence image shows mCitrine-Erk2, the lifetime is 
shown in the middle row and the α map in the bottom row (right). The corresponding average life-
time and the bound fraction α per cell are represented in box Plots (left).  
 
The resulting quantification of the donor fluorescence intensity showed that the 
lowest lifetime and inversely correlated highest α values were measured under 
control conditions in the presence of DMSO. Beside this, the highest variance 
for both parameters was found in the control condition. Upon Deltarasin treat-
ment, the lifetime increases with increasing Deltarasin doses. For 
Deltazinone 1, a similar loss of pErk2 was confirmed by elevated lifetime val-
ues. RNAi-mediated downmodulation of PDEδ resulted in a moderate change in 
the donor lifetime and α, when compared to both inhibitors. 
In accordance with previous observations by Zimmermann et al. already 
demonstrating decreased phosphoErk levels in Western Blots (Zimmermann, 
2012) this data showed the same effect on a molecular basis. It can be con-
cluded that PDEδ inhibition, either by genetic or chemical approaches, has an 
effect on KRas and thereby on downstream molecules as demonstrated by the 
decreased activation of Erk2.   
 58 
 
5.7 Characterization of the mPDAC system 
The panel of genetically modified human cancer cell lines clearly showed a 
strong correlation between the KRas status and the availability of free PDEδ 
inside cells. All human cell lines were were chosen due to their known KRas 
status but derived from various tumor origins. Hence, they represent heteroge-
neous populations and might have acquired additional mutations with time.  
To further allow a direct correlation between the KRas status and the response 
to PDEδ inhibition, two cell lines, derived from genetically engineered mouse 
models, demonstrated to mimic different stages of human PDAC (Hingorani, 
2003; Olive, 2009; Hezel, 2006) were examined in the following experiments. 
The model system has the advantage of a known mutation status as both cell 
lines express oncogenic KRas. The additional p53 mutation is characteristic for 
late stage pancreatic cancer. 
First, these cell lines were screened for the intracellular amount of active Ras. 
Both cell lines, KRasG12D(-/+)(KC, mPDAC 79990) and KRasG12D(-/+)p53R270H(-/+) 
(KPC, mPDAC 79751) are expected to have high levels of GTP-bound KRas 
because of the oncogenic KRas mutation on one allele. Regarding the initiation 
of the MAPK pathway, active Ras recruits cytosolic Raf to the plasma mem-
brane, which binds via its RBD (Ras-binding domain of Raf) exclusively to Ras-
GTP. The binding of RBD to active Ras and its recruitment from the cytosol to 
the plasma membrane are indicators for active GTP-bound Ras. 
In order to demonstrate the presence of active Ras, pulldown experiments with 
purified 3x Raf-RBD were performed. For this, cell lysates of the respective cell 
line, grown under serum conditions, were incubated with GST-tagged 3x Raf-
RBD, pulled down with GSH-beads and loaded on acrylamide gels. The mock 
control was prepared from cell lysates, incubated with GSH-beads but no 3x 
Raf-RBD-GST was present. After Western Blotting, the membranes were 
stained for anti-pan Ras, due to the lack of specific KRas antibodies. A positive 
pan Ras staining indicated the presence of comparable levels of GTP-bound 
Ras in both cell lines (figure 32). The mock control showed only faint and un-
specific bands indicating that the pan Ras staining in the presence of 3x Raf-
RBD was specific. From this it can be concluded that both cell lines express 
active Ras in equal amounts. 
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Figure 30: GST-pulldown experiment with 3x Raf-RBD-GST in both cell lines as depicted above, 
(mPDAC 7999 left and mPDAC 79751 right). Anti-pan Ras staining indicates the presence of acti-
vate Ras in both cell lines, the mock control is derived from lysates without 3x Raf-RBD-GST incu-
bation and subsequent GSH-pulldown. In the double mutant cell line, two pulldown samples with 
different concentrations are shown next to the mock control. 
 
5.8 Raf-RBD-GST immunostaining 
In the presence of GTP-bound Ras, the PDEδ/Arl2 delivery system was shown 
to be crucial for the out-of-equilibrium maintenance of KRas at the plasma 
membrane.  
As shown for the panel of human cancer cells and reported in previous studies, 
a delocalization of KRas from the plasma membrane to endomembranes can be 
observed after PDEδ-specific RNAi treatment (figure 33). In figure  33, the delo-
calization of active Ras was visualized by fluorochrome-labeled 3x Raf-RBD in 
one of the murine PDAC cell lines (Chandra, 2012). 
 
 
Figure 31: Ras staining with 3x Raf-RBD in the double mutant cell line. Active Ras randomly dis-
tributes to endomembranes after PDEδ downmodulation by siRNA. (Figure adapted from Chandra, 
2012) 
 
This experiment could not be reproduced with the aforementioned labeled 3x 
Raf-RBD. That is why an indirect immunostaining approach was designed, 
which will be discussed further. 
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To visualize active Ras, cells were treated with either DMSO or Deltarasin (5 
µM) for 6 h, fixed, permeabilized and incubated with unstained 3xRaf-RBD-
GST. An Alexa 488 conjugated anti-GST antibody was used in the second step 
to detect GST and thereby indirectly active Ras using fluorescence microscopy 
(figure 34). 
 
 
Figure 32: Immunofluorescence with 3xRaf-RBD-GST, followed by anti-GST Alexa488 staining in 
both cell lines with each two samples (single mutant left and double mutant right). The staining 
indicates the presence of activated Ras at the plasma membrane (upper panel). Ras delocalizes 
from the plasma membrane to endomembranes (lower panel) after 6h Deltarasin treatment (5 µM). 
 
The GST-staining in DMSO-treated cells was predominantly visible at the plas-
ma membrane in both models. DMSO treatment was used as the control condi-
tion to exclude possible phenotypic effects caused by DMSO itself, as PDEδ 
inhibitors were all dissolved in DMSO prior to use. As shown in figure 34, 
DMSO seemed to have no effect on the Ras localization at the plasma mem-
brane. After Deltarasin addition, active Ras diluted to endomembranes and the 
peripheral staining dissolved. Dot-like structures appeared in the perinuclear 
area and in close proximity to the plasma membrane. The double knock-in cell 
line was found to have vesicles distributed throughout the cell, whereas the ma-
jority of single mutant cells showed perinuclear accumulation. The mismatch in 
localized fluorescence between DMSO and Deltarasin treated cells evinces that 
Deltarasin binds to PDEδ, interrupts the Ras cycles and causes a randomized 
Ras distribution to all membranes with time. 
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5.9 Effects on KRas localization after PDEδ inhibition 
To further characterize the system and visualize specifically the inhibitor-
induced delocalization of ectopically expressed KRas from the plasma mem-
brane to endomembranes, live-cell imaging was carried out. Fluorescently la-
beled KRas (mCitrine-KRas) was transfected into both cell lines and changes in 
the localization of KRas before and after the addition of Deltarasin or 
Deltazinone 1 were followed over time (figure 35 and 36): 
 
 
Figure 33: Murine PDAC cells were transfected with mCitrine-KRas and acquired before (0 min), 
and 15, 30, 45, and 60 min after 10 µM Deltarasin addition. The single mutant cell line is depicted on 
top and the double mutant cell line on the bottom. 
 
Deltarasin caused cell shrinkage and within 60 min a clear depletion of KRas 
fluorescence from the plasma membrane could be observed in both cell lines. 
With proceeding time, Deltarasin-treated cells became more round-shaped and 
the fluorescence signal seemed to dominantly arise from endomembranes (fig-
ure 35). With low doses of Deltazinone 1, no such clear effects could be moni-
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tored (data not shown) and even with higher concentrations (50 µM) only cell 
shrinkage could be observed in both cell lines (figure 36). 
This indicates that Deltazinone 1 is less effective in targeting the PDEδ/Arl2 
system as there was no visible dilution of KRas to the endomembranes. Alt-
hough both inhibitors possess the same PDEδ binding mode, they are based on 
different chemical scaffolds. Hence, it is likely that theiy obey differences in their 
efficiency or induce unwanted side effects, which could be shown for Deltarasin 
in human cancer cell lines. 
 
 
Figure 34: Murine PDAC cells were transfected with mCitrine-KRas and the fluorescence intensity 
was acquired before (0 min), 5, 10, 15, and 20 min after 50 µM Deltazinone 1 incubation. The single 
mutant cell line is depicted on top and the double mutant cell line below. 
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5.10 PDEδ inhibition affects cell growth in mPDACs 
As Deltarasin was published to have a dose-dependent growth inhibitory effect 
on oncogenic KRas dependent human PDACs (Zimmermann, 2013), the mu-
rine system was also subjected to impedance-based real-time cell proliferation 
measurements, monitored by RTCA (real-time cell analyzer). The measure-
ments were carried out for 4-5 days with 5,000 cells/well in 16-well E-Plates 
where each condition was duplicated. The mean value and the standard devia-
tion were calculated. The real-time acquisition of cell growth was performed with 
varying inhibitor concentrations of Deltarasin and Deltazinone 1, respectively 
(figure 37). 
 
 
Figure 35: Growth response after Deltarasin and Deltazinone 1 administration. The left column 
shows the cell growth after different doses of Deltarasin and the right column after Deltazinone 1 
application. The single mutant cell line (79990) is shown in the upper row and the double mutant 
cell line (79751) in the lower row. The mean value of two parallel measurements under each condi-
tion is plotted. The error bars represent the standard deviation. Deltarasin causes a dose-
dependent response in both cell lines. At 5-7 µM growth is inhibited in the single mutant cell line, 
whereas the double mutant cell line tolerates up to 9 µM. Deltazinone 1 seems to have only minor 
effects on the double mutant cell line at high doses and no effects are visible in the single mutant 
cells. The black arrow indicates the time point of inhibitor addition. 
 
In case of Deltarasin, growth inhibitory effects were visible between 5-7 µM in 
the single knock-in cell line, whereas the double mutant reacts at 9 µM and 
seemed to be more resistant to Deltarasin. The new inhibitor was previously 
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tested in human PDACs and shown to require higher inhibitor concentrations as 
Deltarasin (Papke, 2015). Hence, Deltazinone 1 doses up to 50 µM were ap-
plied to mPDACs. Within 4 days, no reduced proliferation could be observed by 
RTCA in the KRas(G12D) cell line, but the double mutant cell line exhibited ef-
fects on growth, starting at 40 µM. The growth behavior after Deltarasin admin-
istration was more affected than with Deltazinone 1 and in case of mPDAC 
79751, a switch-like response for Deltarasin between 7 and 9 µM was visible. 
Concentrations above 9 µM resulted in immediate cytotoxicity. Although 
Deltazinone 1 was shown to have the same binding mode as Deltarasin and 
less cytotoxic effects (Papke, 2015), only minor growth effects for one cell line 
could be monitored in this timeframe (figure 37, right column). 
The measurable effects on growth by Deltarasin vanish if the cells were initially 
seeded at higher densities (figure 38). Here, the KC cells tolerated Deltarasin 
concentrations >7 µM. The KPC cells showed a change in their growth behav-
ior, starting at 7 µM but less prominent than with lower cell densities. 
 
 
Figure 36: RTCA measurements for both mPDAC cell lines, seeded at higher densities, in the pres-
ence of varying Deltarasin concentrations, as indicated. These doses showed an effect on growth 
in less confluent samples, which was not noticeable here. 
 
5.11 Clonogenic assays to study long-term effects in 
mPDACs 
To further study long-term effects of both inhibitors on growth in the murine cell 
systems, clonogenic assays with varying inhibitor concentrations were per-
formed (figure 39). As shown for the human cancer cell lines, clonogenic assays 
allow discriminating between cytostatic - the colony number remains but the 
size decreases - and cytotoxic effects - reduction of the colony number. 
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Figure 37: Clonogenic assays with varying concentrations of Deltarasin  and Deltazinone 1 for both 
cell lines (top). The KC cell line is depicted in the upper row and the KPC cell line in lower row. The 
quantification for the corresponding inhibitor and cell line is shown below. Deltarasin causes cell 
death at 2.5 µM in long-term studies in both cell lines, whereas Deltazinone 1 seems to have a 
dose-dependent effect only in the double mutant cell line. The DMSO concentration is equal to the 
highest dose of inhibitor used in the experiment. All clonogenic assays were performed in tripli-
cates. 
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Deltarasin treatment for 7 days caused cell death in both cell lines between 2.5-
5 µM, as visualized by the lack of crystal violet staining. Deltarasin concentra-
tions >5 µM were likely to cause unspecific cytotoxic effects due to the abrupt 
change in cell growth (figure 39, top, left).  
The quantification was performed on IR-scanned (Licor, Odyssey) images with 
equal sizes and ImageJ was used to measure the particles of each well. As 
mPDAC cells are highly proliferative, even when sparsely seeded, the well bot-
tom is overgrown by undistinguishable colonies within 7 days. Hence, the quan-
tification information was reduced to measure the plate occupancy because 
single colonies could not be correctly defined. As discussed for the human can-
cer cell lines, an improved particle tracking algorithm would probably give more 
information about the colony number and the colony size. 
Nonetheless, the resulting diagram clearly showed a dose-dependent behavior 
for the KC cell line and the KPC cell line seemed to tolerate increasing 
Deltarasin concentrations up to 2.5 µM (figure 39). In case of Deltazinone 1 the 
growth inhibitory effects are only visible in mPDACs 79751 at high concentra-
tions and for long incubation times, corroborating the RTCA data. Moreover, a 
dose-dependent colony decrease could be observed for the double knock-in cell 
line, whereas the mPDAC 79990 cell line was unaffected even at concentra-
tions >40 µM. The single knock-in cell line was slightly affected by DMSO, as 
indicated in the quantification, because the DMSO concentration was equal to 
the highest inhibitor dose applied in this assay, which could explain the elevated 
percentage of plate coverage at 10 and 20 µM (figure 39, top). The KPC cells, 
harboring the additional p53 mutation seemed to become resistant to Deltarasin 
treatment (figure 39), but clearly showed a long-term effect in presence of 
Deltazinone 1. Interestingly, concentrations of 10 µM Deltazinone 1 and below 
seemed to have no effect on the plate occupancy (figure 40). 
That implies that the new scaffold Deltazinone 1 exhibited less cytotoxicity on 
both cell lines but long-term effects on the KPC cells at higher concentrations.  
 
 67 
 
 
Figure 38: Clonogenic assays with varying concentrations Deltazinone 1 for both cell lines as de-
picted above. The DMSO concentration is equal to the highest dose of inhibitor used in the experi-
ment. Cells are grown for 7 days in the presence of the inhibitor. 
 
In order to allow for a more quantitative statement about the impact of higher 
cell densities on the growth-inhibitory effect of Deltarasin, both cell lines were 
seeded at higher densities and grown for 7 days in the presence of the respec-
tive inhibitor or DMSO (control). From the colony staining it can be inferred, that 
both cell lines die at concentrations >2.5 µM (figure 41). The single mutant cell 
line exhibits a similar staining in all four wells. For the KPC cells, a slight reduc-
tion in the plate coverage at 1.25 µM can be seen by eye. None of the populat-
ed wells could be used for further quantification as there were no distinguisha-
ble colonies. 
 
 
Figure 39: Clonogenic assays with varying concentrations of Deltarasin for both cell lines, seeded 
at higher densities. Deltarasin causes cell death at 2.5 µM. No dose-dependent growth inhibition 
could be observed. The DMSO concentration is equal to the highest dose of inhibitor used in the 
experiment. Cells are grown for 7 days in the presence of the inhibitor. 
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5.12 PDEδ inhibitors break the interaction between RheB 
and PDEδ 
It was already shown that Deltarasin and Deltazinone 1 are able to break the 
interaction between the Ras-family member RheB and PDEδ (Zimmermann, 
2013; Papke, 2015). RheB is a farnesylated but non-palmitoylated protein, 
which also binds to PDEδ. In contrast to KRas it lacks any polybasic motif or 
other feature to localize to a specific trapping membrane compartment hence it 
is enriched on perinuclear membranes. 
To address the question whether the PDEδ inhibitors are also able to break the 
molecular interaction in the murine model system, mCitrine-labeled RheB and 
mCherry-fused PDEδ were transfected in both cell lines and FRET (Förster 
Resonance Energy Transfer) was determined by FLIM (Fluorescence Lifetime 
Imaging Microscopy) in the absence and presence of the respective inhibitor in 
live cells. The genetically encoded fluorophores, mCitrine and mCherry are a 
suitable FRET pair, in which mCitrine functions as the donor fluorophore and 
mCherry as the acceptor. In the absence of any drug, both fusion proteins are 
soluble in the cytoplasm, accompanied with a high RheB fluorescence signal in 
the nucleus. Data analysis reveals initially the binding of RheB to PDEδ indicat-
ed by a higher interacting fraction (α) and a lower lifetime as compared to do-
nor-only or inhibitor-treated samples. 
Upon drug treatment, RheB delocalized to endomembrane structures and its 
fluorescence intensity in the nucleus dropped, indicating less soluble material. 
The lifetime increased and α decreased, confirming the loss of interaction be-
tween the two fluorescently labeled proteins (figure 42). PDEδ is a soluble mol-
ecule and remained soluble throughout the experiment, whereas the RheB fluo-
rescence appeared to be predominantly delocalized to perinuclear membrane 
structures after inhibitor addition. This experiment confirmed that both inhibitors 
are functional in murine cells and they efficiently break the interaction between 
RheB and PDEδ. 
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Figure 40: Deltarasin and Deltazinone 1 break the interaction between RheB and PDEδ in mPDAC 
cells. FLIM images show that RheB and PDEδ interact in the cytosol, as indicated by a lower donor 
lifetime and the increase in the bound fraction (α). After inhibitor treatment, the donor lifetime in-
creased and the inversely correlated bound fraction decreased. The single knock-in cell line is 
shown on the top and the double knock-in cell line on the bottom. Each, 5 µM Deltarasin (left) and 
10 µM Deltazinone 1 (right) were used. 
 
5.13 Effects on MAP kinase signaling after PDEδ inhibi-
tion 
The previous experiments demonstrated that both inhibitors exhibit different 
effects on cell growth in both murine cell lines. Deltarasin gains cytotoxic 
properties at concentrations above 5 µM or even lower for longer incubation 
times, whereas Deltazinone 1 did not. Nonetheless, both compounds break the 
interaction between PDEδ and RheB. That is why it is likely that a perturbation 
of the KRas cycle would have additional effects on downstream signaling. 
As afore mentioned, Ras-induced signaling is transmitted via the MAPK 
pathway, resulting in proliferation. Oncogenic KRas is constitutively active, and 
should therefore enhance the MAPK signaling output. As an activity read-out for 
oncogenic KRas signaling, phosphorylation of Erk - the terminal node of the 
MAPK pathway - was studied by Western Blot. Different concentrations of each 
inhibitor were applied to both cell lines and incubated for 6 h and stained for 
pErk (figure 43 and 44). For data quantification, pErk levels were normalized to 
Cyclophilin B levels. 
 
 70 
 
 
Figure 41: PhosphoErk levels for both mPDAC cell lines in the presence or absence of Deltarasin 
were determined by Western Blots (left). The quantification of three independent experiments is 
shown on the right with the respective standard deviation. In case of the KC cell line, p44 values 
for low Deltarasin concentrations are shown as single values due to the lack of detectable bands. 
Cells were incubated with Deltarasin for 30 h. The phosphoErk and Cyclophilin B bands are shown 
for different Deltarasin concentrations and from their quantification (N=3), it can be inferred that 
the single knock-in cell line (top) and the double knock-in cell line (bottom) have decreased pErk 
level with increasing amounts of Deltarasin. 
 
After Deltarasin incubation for 30 h, a dose-dependent decrease of phosphoErk 
levels (p42, p44) was visible in both cell lines. Regarding the overall trend, 
Deltarasin caused a dose- and time-dependent decrease of pErk levels in both 
cell lines. 
In case of Deltazinone 1, no such effect on downstream signaling after PDEδ 
inhibition neither in the single (data not shown), nor in the double knock-in cell 
line could be detected in this timeframe. The pErk levels were nearly constant in 
each condition (figure 44). 
. 
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Figure 42: PhosphoErk levels after Deltazinone 1 and DMSO treatment (control) in mPDAC cells 
(79751) were determined by Western Blots (left). The quantification of three independent experi-
ments is shown on the right with the respective standard deviation. Cells were incubated with 
Deltazinone 1 for 24 h. The phosphoErk and Cyclophilin B bands are shown for different Deltarasin 
concentrations and from their quantification (N=3) it can be inferred that pErk levels were not af-
fected by increasing amounts of Deltazinone 1. 
 
5.14 Monitoring pErk2 by PhosTag-FLIM in mPDACs 
To further quantify any change in Erk activity in single cells, PhosTag-FLIM was 
utilized (Karajannis, 2015). PhosTag is a phosphate-binding probe, which al-
lows the detection of phosphorylated (serine, threonine, tyrosine) proteins. As 
Erk has to be phosphorylated for its full activity, mCitrine-labeled Erk2 was 
transfected in both cell lines and treated with different amounts of both inhibi-
tors, fixed, permeabilized and stained with PhosTag-Cy3.5. The amount of 
FRET correlates with Erk2 activity (figure 45).  
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Figure 43: Deltarasin treatment reduces the level of phosphorylated Erk2 in mPDAC cells. 
PhosTag-FLIM on (79990) cells with mCitrine-Erk2 (donor) fluorophore and PhosTag-Cy3.5 (accep-
tor). The fluorescence images, the lifetime map and α map of a representative example cell are 
depicted on the left. The respective quantification of the donor lifetime (upper graph) and the 
bound fraction (lower graph) of 2 datasets is shown on the right.  
 
As depicted in figure 45, Deltarasin treatment resulted in a loss of phosphory-
lated Erk2 when compared to the DMSO control condition. In DMSO-treated 
cells a clear phosphorylation gradient of Erk2 in the nucleus and throughout the 
cell could be detected, whereas Deltarasin-treated cells did not exhibit such a 
gradient. For quantification, the average lifetime and α values of the whole cell 
were used. The resulting box plots showed for the average lifetime in >4 cells 
the tendency to increase after Deltarasin addition. DMSO-treated cells usually 
exhibited a higher FRET signal. This indicates that Deltarasin caused a de-
crease in Erk2 phosphorylation.  
Next, Deltazinone 1 was applied to cells with ectopically expressed mCitrine-
Erk2, incubated, fixed, permeabilized and stained with PhosTag-Cy3.5 and 
FLIM was performed (figure 46). 
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Figure 44: Deltazinone 1 treatment reduces the level of phosphorylated Erk2. PhosTag-FLIM on 
mPDAC 79990 (left) and MPDAC 79751 (right) with mCitrine-Erk2 (donor) and PhosTag-Cy3.5 (ac-
ceptor). The fluorescence images, the lifetime map and α map of a representative example cell are 
depicted on the left for the KC and on the right for the KPC cell line with DMSO and 10 µM 
(Deltazinone 1) for both cell lines and 20 µM (Deltazinone 1) for the single mutant cell line. The 
respective quantification of the donor lifetime and the bound fraction (α) of 2 datasets is shown 
below. 
 
Regarding the effects of Deltazinone 1 on downstream signaling, the quantifica-
tion of the FLIM data in both cell lines showed an increased lifetime and de-
creased bound fraction, when compared to the DMSO control and in case of the 
lifetime additionally to the donor-only sample as well. This clearly showed a de-
crease of Erk2 phosphorylation in the presence of both inhibitors after 2 h. 
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5.15 Doxycyclin-inducible downmodulation of PDEδ in 
mPDACS 
The most elegant way to target PDEδ would be genetic downmodulation of 
PDEδ by lentiviral transduction of doxycycline-inducible shRNA in the murine 
models, demonstrated to work in human cells. Previous data with commercially 
available siRNA and transient shRNA indeed showed an effect on pErk in corre-
lation with the amount of downregulated PDEδ (Chandra, 2012). The idea was 
to use the sequence from the commercial shRNA, used by Chandra et al. and 
introduce it into the pLKO backbone. The induction of shRNA (shRNA cloning 
performed by Dr. A. Konitsiotis) showed no significant change in the growth be-
havior in both cell lines (figure 47). In order to prove the downregulation 
efficienciy, Western Blots were carried out and stained for PDEδ. Unfortunately, 
no significant reduction in the band intensities after doxycycline-treatment was 
detectable (figure 49). Hence, the designed construct is not targeting endoge-
nous PDEδ in the murine system and the slight change in the growth behavior 
of the 79990 cells, measured by RTCA, is not caused by a specific 
downmodulation of PDEδ. 
 
 
Figure 45: RTCA data for the respective murine cell line (top). The single mutant cell line is shown 
on the left and the KPC cell line on the right. Doxycycline was added after 24 h. The corresponding 
Western Blot data to show time-dependent downregulation of PDEδ, including CyclophilinB as the 
loading control, is shown below. 
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6 Discussion and conclusions 
6.1 Genetic downmodulation of PDEδ in stably trans-
duced human cancer cell lines 
The initial idea was to generate a panel of human cancer cell lines with stable 
shRNA expression (table 1). For this hPDAC cells (Panc-1, Panc-TUI, Capan-1, 
and BxPC-1), CRC cells (HT-29, HCT-116, Hke-3, and SW480), the lung can-
cer cell lines (A549, H358, and H441) and the cervix carcinoma cells A431 were 
subjected to lentiviral transduction with shRNA against PDEδ. Out of this panel, 
only the lung cancer cell lines H358 and H441 could not be generated because 
they did not tolerate viral infection and subsequent puromycine selection. Even 
with multiple rounds of viral supernatant transfer, shown in parallel to work in 
other cell lines, this did not yield stably transduced cells. Nonetheless, the sin-
gle RTCA measurement for H358 cells pointed in the direction that also here 
oncogenic KRas-dependent cell lines are more affected than KRas wildtype 
cells (A549). 
The subset of hPDACs represent a reproduction from experiments performed in 
2013 (Zimmermann, 2013). As demonstrated in the results section, the re-
sponse in RTCA measurements could be reproduced in this work (figure 17). 
The MIA PaCa-2 cells and the Capan-1 cells were kind gifts from Prof. S. Hahn 
from the Ruhr-University Bochum. The Capan-1 cells I generated in my work 
showed a different behavior after doxycycline induction. Even selection with 
high amounts of puromycine (5 µg/ml) for 2 weeks did not show a stronger 
growth inhibition after doxycycline addition (figure 46). 
 
 
Figure 46: RTCA data for Capan-1 cells under high puromycine selection (top graph). The 
doxcycycline induction is represented by the red curve and shows no significant reduction in cell 
proliferation. 
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Although lentiviral systems provide high and efficient transduction, the insertion 
and positioning of artificial DNA in the genome cannot be controlled. That 
means, whenever a stable cell line is generated, it still remains questionable if a 
good knock-down, in case of shRNA, is achieved. Very likely, the cell lines used 
for the publication in 2013 (Zimmermann, 2013) and for figure 17 (data generat-
ed by Dr. B. Papke for Capan-1), were more efficiently targeted, probably due to 
a more efficient insertion or positioning of shRNA. The reproduction of a new 
stably transduced Capan-1 cell line would not necessarily yield better results, as 
the place of insertion of the viral DNA is not controllable. 
Moreover, the Capan-1 cells, which were generated in this work, exhibited the 
highest amounts of PDEδ levels after doxycycline-induced depletion, as shown 
by Western Blot (figure 16). According to reaction-diffusion simulation data 
(Schmick, 2015), even a small fraction of free PDEδ in the perinuclear area is 
sufficient to maintain KRas at the plasma membrane by the PDEδ/Arl2 delivery 
system. As Capan-1 cells are oncogenic KRas-dependent and were shown to 
react to PDEδ downregulation, the remaining fraction of PDEδ after knockdown 
might be sufficient to prevent cell death hence, the out-of-equilibrium distribution 
is still maintained. In this way, the Western Blot data corroborates the slight 
growth changes observed by RTCA and might provide information why this sys-
tem does not behave as it was supposed to be. 
Nonetheless, the downmodulation of PDEδ was successful in all the remaining 
cell lines, as shown by Western Blots. The data from RTCA measurements and 
demonstrated that KRas-dependent cells are more susceptible to PDEδ 
downmodulation or small molecule inhibition. All human PDACs showed the 
expected sensitivity to PDEδ inhibition, which correlated with the KRas status. 
Interestingly, the CRC cells seemed to be unaffected by modulated PDEδ lev-
els. Only the KRas-dependent cell line HCT-116 showed decreased prolifera-
tion in the absence of PDEδ, whereas the isogenic counterpart Hke-3 did not. 
The most striking behavior could be detected in HT-29 cells. The PDEδ knock-
down worked in these cells, as demonstrated by Western Blots, but they did not 
respond to any PDEδ modulation, neither by RNAi nor small molecule inhibition. 
HT-29 cells have an oncogenic Braf mutation, which is downstream of KRas. 
This means that such cancers are not likely to gain additional Ras mutations 
and that the BRaf mutation alone is sufficient to drive cancer progression. 
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Moreover, BRaf mutations seemed to be unaffected by varying PDEδ levels, as 
BRaf is a soluble protein and does not require a solubilization factor for its dis-
tribution. In addition, the new small molecule inhibitor Deltazinone 1 showed the 
same growth profiles in RTCA measurements as the inducible shRNA did. This 
confirms that PDEδ is a valid target for oncogenic KRas-dependent cancer cells 
and this might offer new therapeutic strategies in cancer treatment. It would 
have been nice to include an additional CRC cell line with a known KRas-
dependency, to really prove the correlation between oncogenic KRas and the 
level of PDEδ and if this is an omnipresent feature of all oncogenic KRas-
dependent cells. 
The clonogenic assays, which were performed in triplicates, showed a smiliar 
growth inhibition in all samples as with RTCA. Again, this proves that the 
knockdown of PDEδ works and is accompanied by long-term growth effects in 
all cell lines. The HT-29 cells displayed again the lowest effect on colony 
growth, concomitant with RTCA data. 
Clonogenic assays with both small molecule inhibitors were also performed by 
Dr.B. Papke and first results showed similar growth effects in the presence of 
Deltazinone 1 and unspecific cytotoxicity with Deltarasin at higher doses. 
To further optimize the information output from clonogenic assays, one has to 
establish better particle tracking methods for the different cells lines to allow for 
better quantification of the colony number and size. All cell lines are from differ-
ent tumor origins and are heterogenous. In this way, it is difficult to identify sin-
gle colonies with a general algorithm and for further quantification an individual 
solution for each cell line is demanding. 
 
6.2 PDEδ inhibition causes a modulated response in 
murine PDACs 
Recapitulating all experimental results, the two mPDAC systems exhibited dif-
ferent behaviors after PDEδ inhibitor treatment. Both cell lines were shown to 
have detectable amounts of GTP-bound Ras, proven by GST-pulldown. GTP-
bound Ras was visualized at the plasma membrane and relocalized to 
endomembranes after Deltarasin treatment, indicating that PDEδ was efficiently 
inhibited and the out-of-equilibrium distribution could not be maintained. Hence, 
the entropic tendency of KRas to occupy all membranes dominated. One draw-
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back is that the RBD-staining detects all Ras isoforms and does not give direct 
information about active KRas. To gain further knowledge, these experiments, 
using 3xRaf-RBD fused to GST could be repeated for both murine cell lines in 
the presence of Deltazinone 1 to achieve better comparability between both 
chemical compounds. It could well be that Deltazinone 1 is not as effectively 
relocalizing KRas, which can already be seen when comparing figure 33 to fig-
ure 34. 
As measured by RTCA, there was a clear difference in the cell indices between 
both cell lines when subjected to increasing Deltarasin concentrations. The 
double knock-in cells seemed to be more resistant than the KC cells. They tol-
erated doses up to 9 µM instead of 5-7 µM and exhibited a switch-like re-
sponse, rather than a gradual dose-response, as measured in the single mutant 
cells. With Deltazinone 1, not even short-term growth effects could be detected 
for the single knock-in cells (figure 35), whereas the KPC cells were slightly af-
fected at higher concentrations and longer incubation times, as demonstrated 
by clonogenic assays (figure 37). Therefore the question arises whether both 
inhibitors exhibit long-term effects on both cell lines. From clonogenic assays it 
could be inferred, that Deltarasin caused cell death at a concentration >2.5 µM 
and Deltazinone 1 seemed to have long-term effects at higher concentrations in 
KPC but not in KC cells (figure 37). 
Beside the higher resistance of KPC cells to Deltarasin, higher cell densities or 
even monolayers prevented inhibitory effects. The dose-dependent growth be-
havior completely vanished when cells were seeded at higher concentrations 
(figure 36). Hence, the elevated level of cell-cell contacts and the increased 
amount of extracellular messengers due to a higher cell number probably pre-
vented cytotoxic effects at the indicated concentrations, which were previously 
demonstrated to cause death in this system (figure 35).  
In a tumor, the phenomenon of cell aggregation and self-organization in time 
and space decreases the susceptibility of single cell in contrast to the organized 
structure. In human pancreatic cancer, chemotherapy was shown to be ineffec-
tive because of collagen-rich shielding layers around the tumor, which provide 
an additional incapability to penetrate central cancer cells (Bardeesy, 2002). As 
a result, certain cells (Hermann, 2007) may have survived any drug or radiation 
treatment and probably additionally gained mutations that guarantee cellular 
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fitness under these conditions and they continue to grow and probably metasta-
size into other organs and tissues (Weinstein, 2006; Marusyk, 2008; Torti, 
2011). 
As demonstrated by FLIM measurements with ectopically expressed RheB and 
PDEδ, an interaction break was indeed observed after addition of Deltarasin or 
Deltazinone 1 within minutes in both murine cell lines. This proves that both in-
hibitors are able to block the PDEδ binding-pocket to release farnesylated car-
go, which dilutes to perinuclear membranes (figure 40). Since both compounds 
demonstrated an interaction break between PDEδ and farnesylated cargo, it is 
likely that a perturbation of the KRas cycle would have additional effects on 
downstream MAPK signaling. Decreased pErk levels were already described in 
the presence of Deltarasin (Zimmermann, 2013). Biochemical data in mPDACs 
by Western Blot confirmed decreased pErk1/2 levels after Deltarasin treatment 
(figure 41) but no decreased pErk levels with the new scaffold Deltazinone 1 
(figure 42). In contrast, PhosTag-FLIM experiments supported the loss of 
pErk1/2 after PDEδ inhibition for both inhibitors (figure 43 and 44). All in all this 
is consistent with previous observations with siRNA/shRNA against PDEδ 
(Chandra, 2012).  
Western Blots represent a cell population, whereas FLIM measurements exhibit 
molecular resolution. This might give an explanation why the Deltazinone 1 
Western Blot data showed no measurable decrease in the Erk2 phosphorylation 
levels. Further data is necessary for better statistical confidence and to really 
prove if there are differences in the murine model systems. 
 
6.3 Higher inhibitor concentrations are necessary to target 
KRas signaling 
The FLIM data in mPDACs and recent studies in MDCK cells (Papke, 2015) 
showed that nanomolar concentrations of both Deltarasin and Deltazinone 1 are 
sufficient to break the interaction between RheB and PDEδ in in vitro assays. 
Nonetheless, it could be demonstrated that even small amounts of unbound 
PDEδ were capable to enrich KRas at the plasma membrane (Schmick, 2015; 
Schmick, 2014a), demanding higher doses of the inhibitor concomitant with cy-
totoxicity. As a consequence, to clearly see effects on Ras relocalization and 
growth, higher amounts of each inhibitor are required to completely block PDEδ 
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and interfere with the Arl2-mediated release in the perinuclear area (Schmick, 
2015), as already demonstrated by in vitro assays (Zimmermann, 2013; Papke, 
2015).  
The conflicting difference in working concentrations could be explained by reac-
tion-diffusion simulations (Schmick, 2015). Although both inhibitors were shown 
to work at nanomolar concentration and RheB-PDEδ FLIM assays, interference 
with the KRas localization requires higher concentration of the respective drug 
(Papke, 2015). Simulations prove that the PDEδ-Arl2-mediated release is inevi-
table for the KRas enrichment at the plasma membrane (Schmick, 2015). Low 
inhibitor concentrations are not sufficient to completely block PDEδ, meaning 
the Arl2-facilitated release is unaffected, which then guarantees a continuous 
fraction of free PDEδ in the perinuclear area. This small fraction of unbound 
PDEδ still exhibits functionality and can solubilize Ras family proteins or rebind 
to the inhibitor, counteracting complete depletion. 
The differences between Ras and RheB localization are consequences of 
membrane leakage and the distinct PDEδ-Arl2 activity, depicted as a waterwork 
in figure 47. The different compartments (plasma membrane and perinuclear 
area) are shown as dams, which function as reservoirs to keep the pool of Ras 
(figure 47, left) and RheB (figure 47, right) in place. Leakage into the endo-
membrane system is represented by holes in the respective dam. The PDEδ-
Arl2 system is compared to a pump and vesicular transport to a pipe, which 
connects both reservoirs. The trapping compartment is shown as an extension 
of the perinuclear area (Schmick, 2015). 
 
 
Figure 47: Schematic waterworks representation of the Ras (left) and RheB (right) localization. The 
plasma membrane and the perinuclear area are shown as dams. The PDEδ-Arl2 complex is repre-
sented by a small turbine which enriches farnesylated cargo in the perinuclear area. All Ras 
isoforms are trapped by their respective trapping compartment and directed to the plasma mem-
brane by vesicular transport (pipe). The RheB enrichment in the perinuclear area requires higher 
PDEδ-Arl2 activity as the leakage from the perinuclear area is fast. Figure adapted from Schmick et 
al., 2015. 
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As already discussed, RheB is farnesylated but lacks any feature, which targets 
it to a trapping compartment. KRas owns an additional polybasic stretch, which 
is able to interact with the negatively charged inner leaflet of the plasma mem-
brane by electrostatic interaction. Therefore, leakage of KRas from the plasma 
membrane is far lower than leakage of RheB from the perinuclear membranes. 
The weaker membrane binding of RheB when compared to all Ras isoforms, is 
demonstrated by a highly leaky perinuclear area. As there is neither a trapping 
compartment, nor directed vesicular transport, a high PDEδ-Arl2 activity is re-
quired to compensate for the loss of RheB in the perinuclear area. This leaki-
ness of RheB in combination with the high PDEδ-Arl2 pumping activity implies 
that perinuclear enrichment is sensitive to perturbations. Therefore, pharmaco-
logical interference with the PDEδ-Arl2 system is likely to affect RheB localiza-
tion more than it does with any of the Ras isoforms. 
In case of HRas, NRas, and KRas, the protein leakage into endomembranes is 
lower than for RheB, as all Ras isoforms harbor distinct features, which allow for 
trapping at a certain membrane compartment. Here, a normal PDEδ-Arl2 pump-
ing activity is sufficient to deplete the cytosolic and endomembrane-bound frac-
tion of Ras to enrich it at its trapping compartment, prior to directed plasma 
membrane transport. 
Regarding the effects on KRas and RheB after PDEδ inhibition, it is questiona-
ble if Erk phosphorylation really reflects KRas-dependent downstream signaling 
or if it is solely caused by affecting RheB. As KRas is involved in a multitude of 
signaling networks, one should consider the connection between PI3K/Akt and 
mTor and additional downstream targets, which could be compared in the pres-
ence of small molecules targeting PDEδ. Combinatorial approaches with a PI3K 
inhibitor (LY295004) could be measured with RTCA and confirmed by Western 
Blot to further untangle the effects on downstream modules. 
Further, it could be speculated that Deltazinone 1, shown to be less cytotoxic as 
higher concentrations are tolerated, affects the mTor pathway (survival signals) 
more than Deltarasin does in accordance with its potency to solubilize RheB. 
The ability to solubilize KRas might completely differ between the tested com-
pounds. As stated above, no KRas delocalization could be monitored with 
Deltazinone 1. Therefore, any growth inhibitory effects might be caused by effi-
ciently targeting RheB. 
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Finally, it has to be determined why Deltarasin and more prominently 
Deltazinone 1 seem to be less effective in the murine system and if it is a result 
of MDR (multi-drug resistance) or if another GSF is present in mice. Another 
GSF might be either exclusively responsible for the solubilization of KRas in 
mice or it can take over PDEδ-mediated solubilization when PDEδ is blocked. 
For Deltazinone 1 a stability test in murine liver microsomes showed that this 
compound is less stable (LDC, Dortmund). Microsomal stability determines the 
intrinsic clearance of the drug in vivo. This might explain why Deltazinone 1 
works in human cell lines but only exhibits effects on mPDAC cells at high con-
centrations and long incubation times. As mouse metabolism differs from the 
human metabolism, the drugs might have been modified in such a way that they 
become effectless by unspecific enrichment (e.g. endomembranes) of the drug 
in the cell. Fluorescently-labeled Deltazinone 1 would indicate whether the cells 
are still able to incorporate the drug and gain insights about the time it stays 
inside. 
 
Although PDEδ is a valid target to inhibit oncogenic KRas-dependent signaling 
in human cell lines, which broadens the spectrum of possible inhibitors that 
would cause alone or in combination a reduction in tumor growth in KRas-
dependent cells, the two murine cell lines behaved completely different after 
small molecule inhibition of PDEδ and among themselves. The results, includ-
ing RTCA, FLIM and clonogenic assay data, point towards the activation of dif-
ferent pathways after inhibitor treatment, as the only genetic difference in the 
murine system is the presence of mutant p53. Hence, new or alternative path-
ways might be activated, as both cell lines exhibit a different oncogenic muta-
tion pattern. In general, this demonstrates that information about the status of 
oncogenes such as KRas or p53 should be evaluated prior to therapeutic 
intervenability. An oncogenic KRas mutation usually has an impact on the 
MAPK signaling pathway. The additional p53 mutation represents a defective 
tumor suppressor, meaning the important cellular check-point p53 has lost its 
function to transmit antiproliferative signals upon stress or oncogene activation 
(Zilfou, 2009). It would be interesting to further study the contribution of each 
oncogenic mutation on the behavior of the system after PDEδ inhibition. 
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7 Outlook 
In this work it was shown, that the genetic downmodulation of PDEδ in human 
cancer models worked out. It would be interesting to see if the effects on 
growth, observed here, could be transferred to other cancer models. It would be 
nice to include an oncogenic KRas-dependent CRC cell line into the panel of 
cells to really correlate the effects on growth with oncogenic KRas-dependency. 
Moreover, the results in lung carcinomas should be reproduced or a transient 
knockdown with siRNA could be performed, as these cells already reacted to 
PDEδ downmodulation but did not tolerate viral transduction. Further, new in-
hibitors with more hydrogen bondings between the PDEδ binding pocket and 
the backbone of the compound could be tested in the human and murine mod-
els. 
The genetic validation of shRNA-mediated downmodulation should be repeated 
in the mPDACs model systems, probably with different cloning methods and 
designs. This would allow a clear statement if the absence of PDEδ is crucial for 
long-term survival in mPDAC cell lines. Additionally, one could state that if the 
cells behave differently, the p53 status is essential for survival. 
It would be interesting to study the effects of PDEδ inhibitors in pancreatic cells 
from the wild-type mouse, which was used as the genetic background for the 
transgenic animals. As these cells are not cancerous, RTCA experiments would 
directly give information about the growth behavior after inhibitor treatment, de-
pendent on the genetic background. 
Moreover, it would be interesting to study the effects of PDEδ inhibition on stem 
cells from different tissues. As the lab is currently establishing organoids from 
the small intestine, the effects on organoid growth and stem cell survival could 
be investigated. Additionally, the organoid system could be expanded to other 
organs (pancreas, liver) and further tested for any effects of PDEδ inhibition. 
In both cell panels, the PhosTag-FLIM approach in the presence of EGF, to 
achieve maximal MAPKK and MAPK activity, could be performed to see clearer 
effects on Ras-mediated signaling via the MAPK pathway. Initial data for Mek1 
phosphorylation in the presence of Deltarasin or Deltazinone 1 pointed also to-
wards deactivation of the MAPK pathway in the presence of small molecule in-
hibitors. Hence, Mek1 activation should also be considered. Further, Western 
Blot data in the presence of Deltazinone 1 could be performed with EGF-
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stimulation to achieve a maximum of phosphorylated Erk2. In this way, a de-
crease of Erk2 phosphorylation should be easier detectable. 
Finally, the MAPK module should be analyzed after shRNA-mediated PDEδ 
knockdown to allow a clear statement about PDEδ inhibition and MAPK signal-
ing and to exclude possible side effects caused by small molecule inhibitors. 
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8 Materials and Methods 
8.1 Molecular biology 
8.1.1 Bacterial culture 
Liquid cultures of Escherichia coli XL 10 Gold/Stbl3 are grown in LB or TB me-
dium with the appropriate antibiotic at 37°C/30°C in an incubator at 180 rpm. 
Cells are plated on LB agar with the appropriate antibiotic (selection marker) 
and incubated at 37°C/30°C. 
Single colonies are picked and inoculated in 5 ml growth medium for mini-prep 
and pre-culturing, respectively. Pre-cultures are transferred to 150 ml medium 
and incubated over night at 37°C/30°C and 180 rpm (midi prep). 
 
8.1.2 Transformation of chemically competent E. coli 
Transformation is an amplification method for recombinant DNA in bacteria. 
For each transformation, 100 µl E. coli cells are thawed on ice, mixed with 3.5 µl 
DTT (2.25 mM) and ~1 µl DNA, and incubated on ice for 30 min, following heat-
shock for 60 sec at 42°C and immediate incubation on ice for 2 min. 500 µl 
SOC medium is added and the transformation mixture is incubated at 37°C for 
1 h while shaking. 10-50 µl are plated on LB agar plates containing the selec-
tion marker and incubated overnight. 
In case of ligation product transformations, all bacteria are completely plated to 
enhance the number of positive colonies. For retransformation, the addition of 
SOC is neglected and 50 µl bacteria suspension is plated after heat-shock. 
 
8.1.3 DNA preparation QIAprep® Spin Miniprep kit 
Typically, 2 ml bacterial culture is used and the procedure is performed accord-
ing to the manufacturer’s protocol. DNA is eluted with H2O for cloning and in 
EB-buffer for long-term storage. 
 
8.1.4 DNA preparation M&N Midi kit (Endotoxin-free 
NucleoBond® Xtra) 
In general, 150 ml cultures are handled according to the manufacturer’s proto-
col for low-copy plasmids. DNA is eluted with H2O (endotoxin-free). Endotoxins 
are amphiphilic lipopolysaccharides located at the outer layer of the inner mem-
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brane of Gram-negative bacteria, such as E. coli. Endotoxins are usually re-
leased during cell growth and during plasmid preparation. Hence, their removal 
is essential to ensure contaminant-free circular DNA and thereby high transfec-
tion rates in mammalian cells. 
 
8.1.5 Sequencing using BigDye® Terminator kit 
Sequencing reactions are based on the Sanger’s dideoxy chain terminating 
method, using fluorescently labeled 2’,3’-dideoxy-nucleotides (ddNTPs) which 
cannot form phosphodiester bonds (missing an OH-bond). The synthesized 
DNA strand is terminated after the insertion of a ddNTP. Nucleotide-detection is 
performed with capillary gel electrophoresis (in-house facility). 
 
Typical sequencing reaction: 
- 500 ng of DNA 
- 2 µl of ready reaction premix 
- 3 µl BigDye® termination buffer 
- 0.5 µl sequencing primer (10 pmol/µl) 
- Adjusted with ddH2O to 20 µl. 
 
Table 2: PCR cycle for sequencing reaction 
 
Step Temperature [°C] Time  
Initial 96°C 1 min 
Denaturation 96°C 10 sec 
Annealing 50 5 sec 
Extension 60 4 min 
 
The denaturation, annealing and extension reaction are repeated 25x (table 2, 
highlighted in grey). Excess ddNTPs are removed using DyeEx® spin columns, 
soaked with 600 µl ddH2O for 30 min prior to use, according to the manufactur-
er’s manual. Cleaned PCR product is transferred to 0.5 ml tubes and dried in a 
speed vacuum centrifuge at 60°C for 30 min and subsequently send for in-
house analysis. 
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8.1.6 Agarose gel electrophoresis 
Electrophoresis is a separation method using electrical fields. Here, the nega-
tively charged DNA migrates towards the anode in the electric field and smaller 
fragments migrate faster, resulting in a separation by fragment size. To be able 
to determine the correct size of a certain DNA fragment, a DNA standard (NEB, 
2-log DNA ladder) is always used for comparison. 
For dsDNA, agarose-containing gels are used. These have the advantage of a 
defined pore size according to the percentage of agarose content. Agarose is a 
polysaccharide and a natural polymer. The appropriate amount of agarose (ta-
ble 3) is dissolved in 1x TAE buffer and heated in the microwave until complete-
ly solubilized and Red-safe is added to visualize DNA (5 µl in 100 ml 1x TAE 
with agarose) and then poured into a gel cast with comb. When cooled down to 
RT, agarose forms a stable hydrogel. Electrophoresis is carried out at 100-120 
V, constant, depending on the size of the gel, for 20-30 min in 1x-TAE buffer.  
 
Table 3: Agarose content and resolution of DNA fragment sizes 
 
Agarose concentration in % [w/v] Size of DNA fragments [kbp] 
2 0.1-1 
1.8 0.2-2 
1.5 0.3-3 
1 0.5-7 
0.8 0.8-12 
0.5 1-30 
 
8.1.7 Purification of DNA 
The QIAquick®/Zymo gel extraction kit for isolation of DNA fragments from 
agarose gels is used to isolate and purify DNA fragments and is performed ac-
cording to the manufacturer’s protocol. Columns with silica membranes facilitate 
DNA-binding at high salt concentrations and allow for washing steps. Purified 
DNA is eluted with H2O. 
 
8.1.8 Restriction digest of DNA 
Restriction endonucleases type II bind to palindromic dsDNA sequences (re-
striction sites) and catalyze the hydrolysis of phosphodiester bonds (3’- to 5’-) in 
each strand, resulting in a double strand break with either sticky or smooth 
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ends. As such, restriction digest is used for cloning, DNA linearization, and liga-
tion experiments. Usually, dsDNA is incubated with the appropriate restriction 
enzyme in 10x CutSmart® buffer (NEB) and H2O for 1 h at 37°C for complete 
digestion. If possible, restriction enzymes are heat-inactivated at 67°C for 30 
min after digestion. 
 
8.1.9 Dephosphorylation of 5’-phosphorylated DNA 
In order to prevent vector DNA from self-ligation, 5’-phosphorylated ends are 
dephosphorylated by alkaline phosphatases (CIAP) during restriction digest. 
Hence, 1 µl CIAP (NEB) is added to each restriction digest of the desired vector 
backbone and incubated for 1 h at 37°C. 
 
8.1.10 Ligation of dsDNA 
DNA-ligase (T4) catalyzes the ATP-driven phosphodiester bond formation be-
tween 3’-OH and the 5’-phosphate group of linear DNA fragments. Ligation of 
DNA fragments is performed with different ratios (1:3 -1:10) of purified and di-
gested vector and insert. The required amount of insert was calculated as fol-
lows: 
 
])[(
])[(][
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ngInsert
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  
 
Usually, 1 µl of T4 ligase and 4 µl ligation buffer were used for each 20 µl reac-
tion and incubated at 16°C overnight. 
 
8.1.11 Polymerase Chain Reaction (PCR) 
The Polymerase Chain Reaction (PCR) is based on thermal cycling (table 4) 
and was developed in the early 1980’s (Mullis, 1986). In general, it is used for 
the amplification of a particular DNA sequence and offers a broad application 
spectrum for e.g. cloning, sequencing, gene analysis, phylogeny, genetic fin-
gerprints, infectious diseases, forensic science, and paternity testing. 
 
Table 4: Thermal cycles of the polymerase chain reaction 
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Step Temperature [°C] 
Initial 95°C 
Denaturation 95°C 
Annealing 45-65 
Extension 60 
 
First, dsDNA is denatured by heat (95°C), resulting in a single stranded tem-
plate, followed by the annealing process of two oligonucleotide primers, flanking 
the region of interest. The hybridization temperature of the primers to the 
ssDNA depends on their length and G-C content and has to be adjusted for 
every primer pair, usually between 45-65 °C. A heat-stable DNA polymerase 
(e.g. Tac polymerase) binds to the specific primers and elongates the primers, 
by consumption of dNTPs, resulting in a perfect copy of the template strand. In 
every cycle the DNA sequence is doubled and cycle repetition leads to an ex-
ponential amplification of the template sequence (table 4, steps in grey are re-
peated). PCR can also be used to create genetic modifications in the template.  
 
8.1.12 PCR product purification 
The QIAquick® PCR purification kit is used for purification of DNA fragments 
according to the manufacturer’s protocol. 
 
8.1.13 Site-directed mutagenesis 
The KRas-SAAX mutant is generated by site-directed mutagenesis because a 
single nucleotide has to be exchanged. As the template, mCitrine-KRas-CLL is 
used. The KRas-SAAX forward and reverse primers are designed to have x nu-
cleotides in length and the nucleotide of interest in the middle. 
  
 90 
 
- 300-500 ng of template 
- 1 µl dNTPs (10 mM) 
- 50 pM primer 1 
- 50 pM primer 2 
- 1 µl Pfu polymerase 
- 10x Pfu polymerase buffer 
- 1.5 µl DMSO 
- Adjusted with H2O to 50 µl 
 
The reaction is performed as following with 16-18 cycles of the steps marked in 
grey: 
 
Table 5: Site-directed mutagenesis PCR cycles, repetitions are shown in grey 
 
temperature time 
95°C 2 min 
95°C 30 sec 
55°C 1 min 
72°C 6 min (1 min/kbp) 
72°C 8 min 
8°C till end 
 
Finally, the methylated parental template strands are digested with Dpn1 at 
37°C for 1 h and the product is transformed into chemical competent bacteria. 
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8.2 Cell culture 
Human pancreatic cancer cell lines, colon rectal, and cervix cancer cell lines 
(Panc-1, Panc-TuI, BxPC-3, MIAPaCa-2, Capan-1, HCT-116, Hke-3, SW480, 
A431) (ATCC, American Type Culture Collection, Manassas, VA, USA) cells are 
maintained in DMEM (Dulbecco’s modified Eagle medium, Sigma-Aldrich 
Biochemie GmbH, Taufkirchen, Germany) supplemented with 10 % FCS (fetal 
calf serum), 2 mM L-glutamine (Sigma-Aldrich Biochemie GmbH, Taufkirchen, 
Germany) and 1 % NEAA (non-essential amino acids) (Sigma-Aldrich 
Biochemie GmbH, Taufkirchen, Germany), at 37°C, 5 % CO2 in a humidified 
incubator. 
Lung cancer cell lines H35 and H441 (ATCC, American Type Culture Collection, 
Manassas, VA, USA) are maintained in RPMI (Roswell Park Memorial Institute 
medium) (Sigma-Aldrich Biochemie GmbH, Taufkirchen, Germany) supple-
mented with 10 % FCS (fetal calf serum), 2 mM L-glutamine (Sigma-Aldrich 
Biochemie GmbH, Taufkirchen, Germany) and 1 % NEAA (non-essential amino 
acids) (Sigma-Aldrich Biochemie GmbH, Taufkirchen, Germany), at 37°C, 5 % 
CO2 in a humidified incubator.  
The colon rectal cancer cell HT-29 and the lung cancer cell line A549 (ATCC, 
American Type Culture Collection, Manassas, VA, USA) are maintained in 
Ham’s medium, supplemented with 10 % FCS (fetal calf serum) and 1 mM L-
glutamine (Sigma-Aldrich Biochemie GmbH, Taufkirchen, Germany), at 37°C, 
5 % CO2 in a humidified incubator.  
 
8.2.1 Cell culture (mPDAC) 
Murine pancreatic ductal adenocarcinoma cells (mPDAC) (Shokat/Tuveson lab) 
were maintained in DMEM, supplemented with 10 % FCS (fetal calf serum), 
2 mM L-glutamine (Sigma-Aldrich Biochemie GmbH, Taufkirchen, Germany) 
and 1 % NEAA (non-essential amino acids) (Sigma-Aldrich Biochemie GmbH, 
Taufkirchen, Germany), at 37°C, 5 % CO2 in a humidified incubator. 
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Table 6: General seeding procedure for mPDAC cells  
 
dish cell density medium 
T75 106 10 ml 
10 cm 106 10 ml 
6-well 150,000 2-3 ml 
8-well LabTek 5,000-10,000 300-500 µl 
RTCA 2,000-5,000 200 µl 
clonogenic assay 250-500 3 ml 
 
 
8.2.2 Cell splitting 
In order to keep adherent cells alive and under perfect growth conditions, they 
need to be detached, diluted and seeded into a new culture dish in a regular 
manner to prevent confluency. This process is called cell splitting. In general, 
adherent cells grow as a monolayer and growth inhibition by confluency might 
transform the cells and as such it is not a controllable and predictable system 
anymore. Old growth medium is removed from the cells and they are washed 
with sterile 1x PBS. Subsequently, Trypsin/EDTA (Pan Bio) is added. Trypsin is 
a digestion enzyme which unspecifically recognizes positive amino acid resi-
dues (Lys, Arg). EDTA (ethylenediamine tetraacetate) functions as a chelator 
and complexes bivalent cations (Ca2+). Adhesion is strongly Ca2+-dependent 
and Trypsin/EDTA facilitates a proper detachment of the cells. The detached 
cells are resuspended in fresh growth media to inactivate Trypsin and to count 
the cells in order to seed them into new culture dishes in the desired amount. 
 
8.2.3 Cryo preservation, thawing, and long-term 
storage of cell lines 
It is essential to keep backups from all cell lines which are used for cell culture 
work for long-term storage in order to generate reproducible results for this work 
and future work. 
For long-term storage, cells are cryo-preserved, using cryo-protectants such as 
DMSO and freezing temperatures below -80°C. DMSO prevents intracellular ice 
crystal formation, hence enhances the cell viability during freezing and thawing. 
Sub-confluent T75 flasks are split as described above, counted and collected by 
spinning down. The resulting cell pellet is diluted in cryo-medium (usually 90 % 
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DMEM and 10 % DMSO) to a concentration of 2x106 cells/ml. 500 µl (106 cells) 
of the cell suspension is applied into cryo vials, stored on ice, and subsequently 
transferred to a NALGENE® Cryo 1°C freezing box and stored at -80°C for at 
least 1 day. These freezing boxes are filled with isopropanol and allow for con-
trolled freezing rates of 1°C/min. The frozen aliquots are moved to a -150°C 
freezer for long-term storage.  
Whenever a certain cell line is needed from the backup, frozen vials are thawed 
as quickly as possible in a 37°C water bath to avoid toxic effects of DMSO on 
the cells. The thawed cell suspension is transferred to an appropriate culture 
dish or flask with the appropriate amount of growth medium. Media is ex-
changed the next day and replaced with fresh growth medium, to remove traces 
of DMSO. 
 
8.2.4 S2 Cell culture and lentiviral transduction 
Murine PDAC cell lines (79990 and 79751), as well as all human pancreatic 
cancer cell lines Panc-1, Panc-TuI, Capan-1, BxPC3, colon rectal cancer cell 
lines HCT116, Hke3, SW480, HT-29, human lung cancer cell lines H441, H358, 
A549 and human epithelial cervix carcinoma cell line A431 are maintained in 
the appropriate medium as previously described. 
All target cell lines are tested for puromycine tolerance, prior to transduction. 
Different puromycine concentrations are applied to each cell line and the growth 
inhibitory effects are monitored for four days. The minimal inhibitory concentra-
tion of puromycine is used for selection (table 7): 
For knockdown experiments, cells are transduced with lentiviral particles con-
taining PDEδ shRNA, vehicle only or GFP-control and selected with puromycine 
(Sigma Aldrich) for minimum 6 days and three passages. 
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Table 7: Target cell lines with their appropriate puromycine concentration for selection after 
lentivirus transfer 
 
cell line puromycine concentration [µg/ml] 
Panc-1 2 
Panc-TuI 1 
BxPC-3 1.5 
Capan-1 1.5-5 
MIAPaCa-2 1 
HCT-116 1 
Hke-3 1 
SW480 1 
HT-29 1 
A431 1 
A549 1 
mPDAC 79990 2 
mPDAC 79751 2 
H358 1.5 
H441 1.5 
 
 
8.2.5 Lentivirus production and transduction 
All vectors are a kind gift of the Hahn lab (Bochum). The design of human 
shRNA PDEδ is published in Zimmermann et al., 2013. 
On the first day, packaging cells (HEK 293 T) are seeded in 10 cm dishes 
(2x106) or 6 cm dishes (105) and cultivated in complete growth medium (DMEM 
with supplements) in a humidified incubator at 37°C, supplemented with 5 % 
CO2. 
On the next day, cells are transfected with a three-plasmid system, using CaCl2 
transfection (1x 10 cm dish). The corresponding concentrations for 6 cm dishes 
are shown in (): 
 
- 12 µg (4 µg) pCMVΔR8.2 
- 6 µg (2 µg) pHIT G 
- 12 µg (4 µg) DNA of interest 
- Ad 438 µl with ddH2O 
- 62 µl (25 µl) CaCl2 solution (2 M) are applied and mixed with the plasmids 
- 500 µl (200 µl) 2x HBS buffer is slowly added (dropwise, no mixing) 
- the reaction mixture is incubated for 10 min at RT 
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The transfection mixture is carefully pipetted up and down and applied to the 
packaging cells. 
On the third day, the growth medium for HEK 293 T is changed and the target 
cells are seeded in 6 cm dishes and incubated overnight at 37°C in a humidified 
incubator with 5 % CO2. 
On day 4, the viral supernatant is collected in a Falcon and filtered through a 
0.45 µm filter in a fresh falcon tube with polybrene (c=4 mg/ml). Growth medium 
from all target cell lines is aspirated and all dishes are washed twice with 1x 
sterile PBS. The filtered viral supernatant containing polybrene is added (2-3 
ml/6 cm dish) to the target cells. The target cells are incubated overnight at 
37°C in a humidified incubator with 5 % CO2. Usually, puromycine selection 
starts the day after with fresh growth medium. 
 
8.2.6 Real time cell analysis (RTCA) 
RTCA is performed using 16-well E-plates with gold electrodes on the bottom 
measured on a Dual Plate xCELLigence instrument (Roche Applied Science, 
Indianapolis IN). The system measures the impedance-based cell index (CI), a 
dimensionless parameter which evaluates the ionic environment at the elec-
trode/solution interface and integrates this information on the cell number. Con-
tinuous impedance measurements are monitored every 15 min for up to 300 
hours. Blank measurements are performed with growth medium. Depending on 
the cell line and if not stated elsewhere, 5×103- 1×104 cells are plated in each 
well of the 16-well plates in 200 μl of cell culture medium for short-term meas-
urements and 1-2x103 cells/well for long-term measurements and then placed 
into the RTCA machine in a humidified incubator at 37°C with 10 % CO2. After 
seeding, cells are allowed to reach steady growth for 24 h before inhibitor addi-
tion, whereas in case of cells stably expressing the inducible shRNA transgene, 
doxycycline is directly applied to the wells of interest. In case of Deltarasin and 
Deltazinone 1 measurements, the amount of DMSO is kept constant between 
the individual conditions and did not exceed 0.24 %. All assays are performed 
as minimum triplicate. The cell index is normalized to 1 at the time point of drug 
administration. For shRNA experiments there no normalization is applied. 
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8.2.7 Clonogenic assays 
To study long-term effects on cell growth, clonogenic assays are performed. 
Briefly, 1,000 cells/well are seeded in 6-well plates and grown for 7-10 days in 
the respective growth medium with or without doxycycline (200 µg/ml) or the 
appropriate amount of inhibitor. Doxycycline and the inhibitors are applied 24 h 
after seeding. Clonogenic assays provide information regarding the colony size 
and the colony number. If the number decreases after inhibitor or doxycycline 
induction, the treatment causes cell death (cytotoxicity), whereas shrinkage of 
the colony is due to cytostatic effects. 
After long-term growth, the medium is aspirated and the wells are carefully 
washed with 1x PBS. 500 µl PFA (Paraformaldehyde) 4 % is applied and 1-
0.5 ml crystal violet solution (5 % in EtOH, prediluted in 1x PBS) is added to 
achieve a final concentration of 0.1-0.05 % crystal violet. The plates are incu-
bated for 20 min at RT and then washed twice with 1x PBS (short 5 min and 
10 min long washing step). The plates are dried at RT and scanned on the Od-
yssey IR imaging System (Licor). Scanned plates are analyzed by counting and 
measuring the colonies with ImageJ. 
 
8.2.8 Inhibitor treatment 
In general, both inhibitors Deltarasin and LDC 09577 are dissolved in DMSO. 
For dilutions, growth medium is used and added before the inhibitor and then 
mixed. 
 
8.2.9 Transient transfection 
All transient transfections in mPDAC and Panc-TUI cells are performed with 
Lipofectamine 2000 (Invitrogen). For this 240 µl OptiMem (Sigma) are mixed 
with 4 µg DNA in one tube. In a separate tube, 240 µl OptiMem and 9.6 µl 
Lipofectamine are applied. Both tubes are first incubated for 5 min at RT and 
then pooled and further incubated for 20 min at RT. 60 µl are applied to each 
well for an 8-well LabTek chamber. 
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8.3 Biochemistry 
8.3.1 Whole cell Lysates 
For protein analysis (Western Blots) whole cell lysates are prepared from 
mammalian cells cultured in petri dishes, according to the needed amount of 
total protein (6-well plates, 3.5 cm, 6 cm, and 10 cm dishes). The growth medi-
um is aspirated and the cells are washed once with PBS, subsequently incubat-
ed with an appropriate amount of 1x RIPA buffer, supplemented with 1 tablet 
Complete Mini EDTA-free protease inhibitor and 100 µl phosphatase inhibitor 
cocktail 1 and 2. After 15 min, the cells are scraped with a plastic cell-scraper 
and the lysed content of each well is transferred to a prechilled 1.5 ml 
Eppendorf tube. If necessary, sonification for 12 sec is performed (30 % cycle 
3). Samples are spun down at 14,000 rpm for 20-30 min and the supernatant is 
collected in fresh prechilled tube. 
At this stage the samples can either be snap-frozen for long-term storage at -
80°C or the total protein concentration is measured by Bradford assay. A BSA 
(bovine serum albumin) standard curve is recorded for calibration. All steps are 
performed on ice and in prechilled machines and tubes to avoid protein degra-
dation. 
 
8.3.2 Bradford assay 
The Bradford assay is a colorimetric protein determination assay, based on the 
absorbance shift of Coomassie Brilliant Blue G-250 dye in presence of protein. 
Coomassie Brilliant Blue G-250 is red in its unbound, cationic form. Upon bind-
ing of the dye to proteins, the blue, anionic form is stabilized and the amount of 
blue complex is equivalent to the protein concentration. The absorbance is 
measured at 595 nm in a spectrometer. 
Protein standards are prepared by serial dilution of BSA (1 mg/ml) in ddH2O. 
16 µl BSA is mixed with 984 µl H2O and a serial dilution out of this, ranging from 
1-16 μg/μl is performed. Each standard (500 μl) is added in a separate cuvette 
and mixed with 500 μl Bradford reagent. For each sample, 1 μl is added to 
500 μl ddH2O and mixed with 500 μl Bradford reagent. The absorbance values 
are obtained at 595 nm in a spectrophotometer and plotted against the standard 
protein concentration. 
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8.3.3 SDS-PAGE 
SDS-PAGE is a method to separate proteins according to their size by electro-
phoresis in acrylamide gels. Sodium dodecyl sulfate (SDS) is an anionic surfac-
tant which stoichiometrically binds proteins (1 SDS molecule per 2 amino ac-
ids). It breaks hydrogen and disulfide bonds, shields the overall charge, and 
causes an unfolding of proteins, resulting in negatively charged complexes 
which are separated only by size. The uniformly charged SDS-protein complex-
es migrate towards the anode when subjected to an electrical field. Smaller 
molecules migrate faster and the distance of migration is proportional to the 
pore size of the polymerized acrylamide gel. Different percentages of acryla-
mide allow a better separation and resolution for characteristic band sizes, de-
pending on the molecular weight of the protein. Discontinuous gels are used in 
all experiments, consisting of a stacking and separation gel. 
Separating gels are poured first and then covered with 100 % ethanol (EtOH) to 
avoid drying of the gel air interface. The gel is allowed to polymerize for 30 min. 
The ethanol is removed and the stacking gel is poured on top, followed by the 
immediate insertion of a comb. The acrylamide gel is allowed to polymerize for 
30 min and then wrapped in foil and stored under humidified ddH2O conditions 
at 4°C. 
 
8.3.4 Sample preparation and gel loading 
Cells were usually seeded one day prior to stimulation, inhibitor treatment 
(Deltarasin, LDC 09577) or transfection. 
Whole cell lysates are mixed with 5x SDS sample buffer and heated for 5 min at 
95°C to allow the denaturation of protein by reduction with 2-mercaptoethanol 
(β-mercaptoethanol). Samples are spun down prior to loading. Prior to electro-
phoresis, the combs are removed from the gels and the sample pockets are 
cleaned with ddH2O and gels are inserted into BioRad Gel chambers 
(TetraCell), filled with 1x running buffer and samples are loaded in their respec-
tive pocket. For size determination of separated proteins, 3 μl (Dual-Color 
BioRad) standard, containing different bands of known molecular weight are 
loaded in at least one well/gel. Empty pockets are loaded with sample buffer 
and electrophoresis is performed with constant voltage of 80 V until samples 
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leave the stacking gel, followed by an increase to 110 V for 2 h until leaving the 
separation gel.  
 
8.3.5 Western Blot 
One form of immuno-blotting is Western Blotting. In this technique proteins that 
are separated electrophoretically are transferred to a PVDF (Immobilon, Milli-
pore, Billerica, MA, USA) membrane to enable immunological protein detection 
with primary and secondary antibodies. After electrophoresis blots are assem-
bled in wet blot modules. PVDF membranes are activated for 30 sec in metha-
nol, then left to equilibrate in 1 x transfer buffer together with the gel and two 
pieces of thin filter paper (Whatmann) and sponges. The blot sandwich is as-
sembled in the following sequence: sponge, filter paper, gel, PVDF membrane, 
filter paper, and sponge. The transfer is carried out at 100 V for 60 min. Follow-
ing transfer, the PVDF membrane is transferred to a Li-Cor® incubation box and 
blocked with blocking buffer (Li-Cor® Biosciences) for 1 h at RT on a shaker to 
saturate unspecific binding sites. The membranes are then incubated with pri-
mary antibodies diluted in 1 ml Li-Cor® blocking solution. PVDF membranes are 
sealed in a plastic bag and incubated overnight at 4 °C in presence of the anti-
bodies. On the next day, the blots are washed 3x with TBS-T for 5 min and then 
incubated with the appropriate secondary IR-antibodies (diluted 1:5,000) diluted 
in 5 ml Li-Cor® blocking buffer on a shaker at RT. Finally, blots are washed 3 
times, 10 min each with 0.1 % TBS-T solution and specific bands are detected 
with the Odyssey Imaging System (Licor, Lincoln, Nebraska USA). 
Antibody Stripping was performed with NewBlot PVDF stripping solution (Licor, 
Lincoln, Nebraska USA) according to the manufacturer’s manual. Membranes 
were incubated in 1x working solution for 20’ at RT. 
 
8.3.6 Primary antibodies 
The following primary antibodies are used for Western Blots in the appropriate 
dilution in Li-Cor® blocking solution. 
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Table 8: List of primary antibodies used for Western Blot 
antigen host dilution company order # 
PDE6D goat 1:200 SCBT sc-50260 
pan Ras mouse 1:1,000 Calbiochem  
pErk rabbit 1:1,000 CellSignaling 9106 
tErk rabbit 1:1,000 CellSignaling 9102 
Cyclophilin B rabbit 1:2,000 Abcam ab16045 
 
8.3.7 GST-pulldown 
For GST-pulldown experiments, 30 µl 50 % Glutathione Sepharose 4B slurry 
(GE Healthcare) with a binding capacity > 5 µg GST/µl were used for each 
sample. To equilibrate the beads, they are washed 4x with 1 ml GST-buffer 
(4°C, 500 g, 5 min). After the final washing step, 100 µl liquid remain on top of 
the beads. In the next step, 150 µg GST-labeled 3x Raf-RBD is incubated for 
30 min at 4°C on a rotating wheel. The beads are then washed 4x with 1 ml 
GST-buffer to remove unbound protein (4°C, 500 g, 5 min). Lysates from 10 cm 
dishes are washed with cold 1x PBS scraped with 1 ml GST-buffer, centrifuged 
and the supernatant is further processed. The lysate is incubated with the equil-
ibrated beads for 30-40 min at 4°C on a rotating wheel. After incubation, the 
beads are again washed 2x with 1 ml buffer to remove unbound protein (4°C, 
500 g, 5 min). After the last washing step, remaining liquid is aspirated with a 
cannula. 25 µl 2x SDS sample buffer is applied, vortexed and the mixture is 
heated for 5 min at 95°C. The samples are loaded on 15 % acrylamide gels. 
 
8.3.8 GST-staining 
8-well LabTek chambers, containing Deltarasin-treated (6 h, 5 µM) and untreat-
ed cells are removed from the incubator and washed with 1x PBS (phosphate-
buffered saline). 200 μl 4 % PFA (paraformaldehyde, w/v) is added to the cells 
and incubated for 5 min at RT. The cells are subsequently washed twice with 
500 µl 1x TBS (Tris buffered saline) and permeabilized with 200 μl 0.1 % 
TritonX100 in 1x TBS for 5 min at RT. In order to remove remaining detergent, 
all samples are washed 3x with 500 µl PBS for 5 min at RT and then blocked 
with blocking buffer (1x PBS with 3 % BSA) for 30 min. After blocking, the block-
ing solution is removed by 3 washing steps with 500 µl 1xPBS for 5 min at RT. 
15-30 μg/ml 3x Raf-RBD-GST solution in blocking buffer is added and incubat-
ed for 1h. After primary staining the samples are washed 3x with 500 µl 1x PBS 
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for 5 min at RT and then stained with a-GST A488 antibody 1:50 for 1 h in 
blocking buffer, in the dark. Finally, the cells are washed 3x with 500 µl 1x PBS 
for 5 min at RT and stored in 1x PBS until use. 
 
8.3.9 Immunostaining for pan Ras 
Usually, 5,000 cells/well are seeded in 8-well LabTek chambers and grown over 
night. In CRC and lung cancer, the doxycycline induction was 72 h prior to fixa-
tion and in hPDAC cells doxycycline is incubated for 24 h. Deltarasin and 
Deltazinone 1 treatment starts 2 h prior to fixation. Cells are removed from the 
incubator and 2x washed with 1x PBS (phosphate-buffered saline). 300 μl ice-
cold Methanol is added to the cells and incubated for 10 min at -20°C. The cells 
are subsequently washed 3x with 500 µl 1x PBS and then blocked with blocking 
buffer (Li-Cor®) for 1 h. After blocking, the primary antibody (pan Ras, 
Calbiochem) is diluted 1:200 in Li-Cor® blocking solution and incubated for 1 h 
at RT (200 µl/well). In order to remove remaining primary antibody, all samples 
are 3x washed with TBS-T for 2-5 min. Alexa488-labeled donkey anti-mouse 
antibody is diluted 1:1,000 in Li-Cor® buffer for 1 h (200 µl/well). Finally, the 
samples are 3x washed with TBS-T and stored at 4°C in the dark until use. 
 
8.3.10 Protein labeling with Cy3.5 
Using a succinimide ester of a sulfoindocyanine (Cy) dye, in a water-free envi-
ronment, it is possible to label proteins specifically. Succinimide esters bind co-
valently to free ε-amino groups on lysine residues or alpha amino acid groups of 
the protein. 
Cy3.5 (Fluorolink Cy 3.5 Monofunctional Dye, GE Healthcare, (PA23501)) is a 
monofunctional dye with a size of 1,102 kDa. Lyophilized Cy3.5 is diluted in 5 µl 
water-free DMF (N,N-Dimethylformamide, Sigma Aldrich). The concentration of 
the dye is measured in a cuvette at 584 nm (1:10,000 dilution of Cy3.5 in PBS). 
The concentration of Cy3.5 can be determined following the Lambert Beer law: 
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Where d is the length of the cuvette (1 cm), c is the concentration in M, A is the 
absorption at a specific wavelength and ε is the extinction coefficient. 1 mg 
streptavidin (Sigma, Aldrich) is dissolved in 1x PBS and washed 2x with 1x PBS 
(1,000 g, 1-2 min) using an Amicon 30 kD cut-off vial. The concentration is de-
termined at 280 nm (1:100 dilution in 1x PBS). The extinction coefficient of 
160,000 M-1cm-1 is assumed, as streptavidin consists of four subunits with an 
extinction coefficient of 40,000 M-1cm-1 per domain. 
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10 % Bicine (1 M, pH 9) is added. A 10-fold molar excess of the dye is calculat-
ed and slowly added to the protein solution and incubated for 18 min in the dark 
at RT. In order to avoid protein denaturation caused by DMF, the volume of 
Cy3.5/DMF must not exceed 10 % of the total volume. The reaction is terminat-
ed with 10 mM Tris buffer (0.2 M, pH 6.5) and subsequently incubated for 
15 min at RT. 
The excess of unbound dye molecules is removed by gel filtration (Protein De-
salting Spin Columns, Thermo Scientific, (89862)), according to the manual. 
Calculation of final D/P ratio: 
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Typically three to four Cy3.5 molecules (Acceptor) should be bound to one pro-
tein molecule, in order to be able to quantify the experimentally obtained FRET 
(Grecco, 2010; Wouters, 1999). 
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8.3.11 PhosTag labeling with Streptavidin 
Streptavidin can be labeled with Cy3.5 in order to use it as an acceptor for 
PhosTag-FLIM (Karajannis, 2015). Streptavidin consists of four identical subu-
nits. Each of these allows the binding of biotin (Vitamin H). This system shows 
one of the strongest non-covalent binding affinities in biology (Ka ~ 10
14–1015 
M−1). PhosTag (Phos-tag™BTL-104Wako Pure Chemicals Industries) is a 
probe which allows the detection of phosphorylated tyrosines, threonines, and 
serines (figure 52). Originally, it was developed for western blots to detect 
phosphor-specific bands. Moreover it can be used as a PhosTag-Biotin-
Streptavidin complex in fixed cells, where it binds to fluorescent proteins and 
allows the detection of FRET.  
 
 
Figure 48: Schematic representation of PhosTag-Biotin bound to phosphorylated protein and 
Streptavidin. Figure adapted from Wako Pure Chemicals Industries. 
 
For this, 474 µl TBS-T (Tween 0.1 %) are mixed with 20 µl Zn(NO3)2 (stock: 
10 mM), 3 µl PhosTag-Biotin (figure 53) solution and 3 µl prelabeled Streptavi-
din-Cy3.5 (previous chapter). All ingredients are multiplied by 4, in order to 
achieve a total volume of 2 ml, mixed and incubated for 30 min at RT. Purifica-
tion is performed with 5 ml size-exclusion columns (Zeba Spin Desalting Col-
umns, 40 kDa MWKO, Thermo Scientific (87771)). 
 
Figure 49: Chemical structure of PhosTag-Biotin 
 
For sample preparation, a Phostag-PB-Cy3.5 ratio of 1:4 in TBS-T is used. 
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8.4 Studying protein states and activation using fluores-
cence-based techniques 
Fluorescence-based approaches have strongly evolved over the past decades 
and became useful research tools in many disciplines. Especially in systems 
and molecular biology, these methods have a great impact and allow nowadays 
even single-molecule resolution. In 1998, the use of genetically encoded 
fluorophores (fluorescent proteins, FPs) was introduced and precise targeting of 
a certain protein was realized (Tsien, 1998). By creating such chimerical fu-
sions, spatial and temporal profiles of proteins of interest can be observed and 
further used for quantitative research, answering basic questions about localiza-
tion, function, and activity.  
Several parts of the work presented in this thesis are based on state-of-the-art 
fluorescence microscopy techniques and will be discussed in more details in the 
following chapters. 
 
8.4.1 Photophysics of fluorescence and FRET 
Fluorescence is a random event and defined as the emission of a photon from 
an electron in the excited state to the ground state (figure 54). The relaxation to 
the ground state by radiation of a photon (fluorescence) is usually in the ns 
range. 
 
 
Figure 50: Jabloski diagram, which shows that a donor molecule is excited with light (dark blue), 
following excitation the donor molecule comes back to the ground state (light blue) and transfers 
energy without radiation to the acceptor fluorophore, which absorbs the energy (green) and emits 
light (yellow) that differs from the excitation (red-shifted) 
[http://www.zeiss.com/C12567BE00472A5C/GraphikTitelIntern/FRETNo_3/$File/FRET-pic03.JPG], 
09.03.2015 
 
The Jablonski plot shows that a donor molecule is excited with light (dark blue) 
while relaxation back to the ground state (light blue), energy is transferred with-
out radiation to the acceptor fluorophore, which absorbs the energy (green) and 
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emits light (yellow) that differs from the excitation (red-shifted). The non-
radiative transfer of energy is called Förster Resonance Energy Transfer 
(FRET) (Förster 1948) and a result of dipole-dipole coupling of nearby 
fluorophores. If the transition dipoles of each chromophore oscillate with the 
same frequency, energy can be resonantly exchanged. The rate of energy 
transfer kT depends on the lifetime of the donor (τ), on the Förster radius 
6
0R  
(usually between 3-9 nm) and the distance r. 
 
6
01 






r
R
kT

 
With 
 6
1
423
0 )(1078.9 DQJnR 
   
 
Where κ2 is the relative dipole-dipole orientation factor with values between 0 
and 4. In the Förster equation it is assumed to be 2/3 for unrestricted isotropic 
motion. The dipoles have to be parallel oriented for efficient energy transfer. A 
perpendicular orientation allows no efficient transfer. J(λ) represents the spec-
tral overlap integral between the donor emission and the acceptor excitation 
spectrum. The quantum yield of the donor QD is a measure for the ratio be-
tween emitted and absorbed photons and the fluorescence lifetime τ. The index 
of refraction is represented by n. 
For FRET to occur, the emission spectrum of the donor has to overlap with the 
excitation spectrum of the acceptor (J(λ)). Both fluorophores have to be in close 
proximity and in the right orientation (κ2).  
 
If FRET occurs, the energy transfer efficiency E can be calculated. The energy 
transfer efficiency is the ratio between transferred and absorbed photons by the 
donor fluorophore and describes a switch-like function (figure 55). 
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Figure 51: Energy transfer efficiency versus distance shows a switch-like curve. The Förster dis-
tance gives 50 % energy transfer efficiency. [http://micro.magnet.fsu.edu, 09.03.2015] 
 
8.4.2 Fluorescence lifetime imaging microscopy 
(FLIM) 
FLIM (Fluorescence Lifetime Imaging Microscopy) (Gadella, 1993; Bastiaens, 
1999; Grecco, 2010) is a powerful tool to measure the fluorescence lifetime of a 
fluorophore and is sensitive to the molecular environment of that fluorophore. 
FLIM is a well-established method to quantify FRET and thus determine protein-
protein interactions or protein conformational changes. In general, the concen-
tration of the probe is not known and within reasonable limits FLIM can be inde-
pendent of the local probe concentration. Only the intensity of the fluorophore 
depends on concentration whereas the fluorescence lifetime is mostly inde-
pendent. Due to the occurrence of FRET and the consequent shortening of the 
donor lifetime, these measurements imply high signal specificity because only 
the donor, which is associated to the molecule of interest, is detected. 
The donor lifetime τD in the excited state is reduced by radiative and non-
radiative processes (kr and knr) and additionally by the resonance energy trans-
fer rate kFRET if an acceptor is present (τF). 
. 
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In this work, only data obtained by time-domain FLIM is presented. The time-
domain information is obtained by exciting the sample with a discrete optical 
pulse (LED, picosecond laser) to observe the decay of the fluorescence lifetime. 
The decay curve can be directly acquired after excitation if the pulse of light is 
very short. The pulse width is kept preferably much shorter than the decay time 
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τ of the sample. In case of donor-only samples a single exponential decay is 
observed: 
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The time-dependent intensity is measured following the excitation pulse and the 
decay time in mono-exponential functions is calculated from the slope of the 
semi-logarithmic plot of the intensity versus the time (figure 56). 
 
 
Figure 52: Mono and multi-exponential decays upon excitation; 2 represents a second fluores-
cence lifetime, i.e. donor-acceptor approaches. 
[http://micro.magnet.fsu.edu/, 09.03.2015] 
 
If two fluorophores undergo FRET there are two different lifetimes present and 
the intensity decay becomes a double exponential function. Donor molecules 
interacting with the acceptors have a faster exponential decay, as represented 
by the second lifetime (τF). 
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The lifetime τis the inverse of the total decay rate hence reflecting the average 
amount of time a fluorophore remains in the excited state following excitation. τ 
is determined by the slope or by fitting the data with global data analysis. The 
pre-exponential coefficients A and B represent the contribution of each popula-
tion to the total signal. From these coefficients the bound fraction α of donor 
molecules bound to acceptor molecules can be calculated (Lakowicz, 2006). 
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The approach assumes that two different protein states exist, present in every 
pixel and associated with a unique donor fluorescence lifetime in the presence 
(τF) or absence (τD) of FRET. The average lifetime of donor-only samples and 
the decreased lifetime due to FRET can be used to calculate the energy trans-
fer efficiency. 
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8.4.3 FLIM sample preparation 
In general, cells were seeded with an amount of 5 · 103-104 cells per well on 8-
well Lab-Tek chambers (Nalge Nunc International, Rochester, NY, USA) or with 
an amount of 2 · 104 cells per well on 4-well Lab-Tek chambers and grown 
overnight. Higher amounts of cells resulted in confluency and lower transfection 
efficiency. 24 hours after seeding, transient expression of plasmid DNA was 
initiated after transfection (Lipofectamine 2000, Invitrogen). The cells were 
transfected over night with purified plasmid DNA and the transfection efficiency 
was determined under fluorescent light the day after. 
Samples for PhosTag-FLIM are fixated with 4 % Paraformaldehyde for 5-7 
minutes at room temperature after inhibitor/doxycycline treatment the cells, 
washed with 1x TBS (5 min, 10 min, 5 min washing steps) and subsequent 
permeabilized with 0.1 % Triton-X-100 in 1x TBS for 5 min and then washed at 
least three times with 1x TBS-T. PhosTag solution is diluted 1:4 with 1x TBS-T 
and incubated with the sample for 1 h in the dark. All PhosTag stainings are 
performed with the recommended buffer recipes for PhosTag-biotin. 
  
8.4.4 Confocal-FRET/FLIM data 
To acquire confocal TCSPC images, a LSM Upgrade Kit (PicoQuant, Berlin 
Germany) attached to a Fluoview 1000 (FV-1000) microscope (Olympus 
Deutschland GmbH, Hamburg, Germany) with a 63x/1.35 NA oil objective is 
used. For time-domain FLIM measurements, a 507 nm pulsed diode laser (LDH 
507, PicoQuant, Berlin, Germany) is used as excitation source (25 ns pulses). 
Spectral filtering is performed with a narrow-band emission filter (HQ 525/15, 
Chroma) and a dichroic filter 530/11 HQ (AHF Analysentechnik AG, Tübingen, 
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Germany) filter, is used to detect the emitted photons using a Single Photon 
Avalanche Photodiode (SPAD, PDM Series, MPD). FLIM measurements are 
recorded with the SymPhoTime software (PicoQuant, Berlin, Germany). Each 
FLIM measurement has a minimum of total 500 photon counts for donor-only 
samples and in presence of acceptor ~300 photon counts per pixel are ac-
quired. 
 
8.4.5 Global data analysis 
FLIM measurements were performed with the SymPhoTime software (Pico-
Quant, Berlin, Germany) and the resulting .pt3 or .ptu files were subjected to 
MatLab (Mathworks) based global data analysis. Using a polar plot, the intensity 
of each pixel, as well as the arrival time of each photon is represented as a 
cloud on the half circle. This is first performed for donor-only measurements. 
The mean value of the cloud reflects the average lifetime of the fluorophore in 
its excited state. The pixel information of D-A images is processed in the same 
way, whereas α, the bound fraction is represented as a line between the mean 
value of the donor-only cloud, as well as the D-A cloud (figure 58). 
 
 
Figure 53: The spatially invariant global lifetimes τF and τD define the FRET efficiency (E), obtained 
by a linear fit of the Fourier coefficients (imaginary and real R). Data sets are globally analyzed and 
α in each pixel is calculated. Figure adapted from Grecco, 2010. 
 
All images are processed in a stack-wise manner. First, all intensity images are 
corrected for background pixels, using the BG subtraction plugin (ImageJ). 
Second, masks are generated for each image and then multiplied with the cor-
responding dc, lt, and alpha stacks. The resulting α maps and lifetime images 
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are set to the same range. The Rainbow smooth colour table was used to dis-
play the resulting differences in alpha and lt images. 
 
8.5 Laser Scanning Confocal Microscopy (LSCM) 
Confocal images of corresponding FLIM samples of live and fixed cells are ob-
tained with an Olympus FluoView FV1000 confocal laser-scanning microscope. 
mCitrine is excited with the 488 nm line of a multiline Argon laser and Cy3.5 
with the 561 nm line of a DPSS laser. Excitation light is focused into the sample 
by a 60x/1.35 NA oil objective using either the DM405/488/561/633 or dichroic 
mirror. Green and Yellow FPs are collected between 498-551 nm and through a 
SDM 560 for sequential imaging with the 561 nm laser. Live cell imaging was 
performed in an incubation chamber adjusted to 37 °C, while fixed cells experi-
ments were performed at RT (~30°C). 
 
8.6 Leica SP5 
For live cell experiments in inhibitor-treated cells (KRas delocalization studies) 
and for pan Ras immunostainings, confocal laser scanning microscopy is per-
formed with a Leica TCS SP5 DMI6000 microscope equipped with a HCX PL 
APO 63x 1.4-.6 NA Blau CS objective and an environment control chamber 
maintaining 37°C and 5 % CO2. The excitation wavelength is selected by 
acousto-optical tunable filters (AOTF) and scanned over the sample at frequen-
cies ranging from 200-600 Hz. The emission signal is passed through a pinhole 
to control confocality and detected by PTMs (photon multiplier tube), whose 
sensitivity can be adjusted by manipulating the applied gain voltage. Confocality 
is controlled by limiting pinhole-size to between 1.0 and 1.5 Airy units. Yellow 
fluorescent proteins (mCitrine, Alexa488) are excited with the 514 nm Argon line 
and the emission is filtered between 525-560 nm. In all cases, scanning is per-
formed in line-by-line sequential mode with 2x line averaging.  
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9 Buffers and Recipes 
9.1 PFA preparation 
In order to prepare 4 %PFA in PBS, 2 g PFA powder were diluted in 45 ml H2O. 
10 µl 1 N NaOH are added to increase the pH. The whole mixture is heated up 
to 65°C for 10-20 min and mixed every 2 min. After complete solvation of the 
powder 5 ml of 10x PBS are added and the liquid is pressed through a sterile 
filter (pore size 45 µm). PFA is stored at 4°C or as frozen aliquots and protected 
from light to avoid decomposition of the polymer. 
 
9.2 Lysogeny broth 
1 % tryptone (10 g/l) 
0.5 % yeast extract (5 g/l) 
1 % NaCl (10 g/l) 
 
9.3 Terrific broth (1 liter) 
1.2 % tryptone (12 g/L)  
2.4 % yeast Extract (24 g/L) 
0.94 % (72mM) dipotassium phosphate (K2P04) (9.4 g/L) 
0.22 % (17mM) monopotassium phosphate (KH2P04) (2.2 g/L) 
0.4 % glycerol (4 g/L) 
 
9.4 SOC medium (1 liter) 
0,5 % yeast extract (5 g/l) 
2 % tryptone (20 g/l) 
10 mM NaCl (0.6 g/l) 
2.5 mM KCl (0.2 g/l) 
10 mM MgCl2 
10 mM MgSO4 
20 mM glucose 
 
9.5 Stacking gel  
0.5 M Tris buffer, pH6.8 
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9.6 Separation gel 
1.5 M Tris buffer, pH 8.8 
 
 
9.7 10x TAE 
Dissolve 242 g Tris in 500 ml H2O 
Add 100 ml 0.5 M Na2EDTA (pH 8.0) and 57.1 ml glacial acetic acid 
Adjust volume to 1 liter with H2O 
Store at RT 
 
9.8 10x PBS 
Dissolve 80 g NaCl, 2 g KCl, 26.8 g Na2HPO4-7H2O and 2.4 g KH2PO4 in 
800 ml H2O 
Adjust to pH 7.4 with HCl 
Adjust volume to 1 liter with H2O 
Divide in aliquots and sterilize if necessary 
Store at RT 
 
9.9 1x TBS 
Dissolve 6.05 g Tris (50 mM) and 8.76 g NaCl (150 mM) in 800 ml H2O 
Adjust pH to 7.5 with 1 M HCl 
Adjust volume to 1 liter with H2O 
Stable for 3 months at 4°C 
 
9.10 1x TBS-T 
Dissolve 1 ml Tween 20 in 1 liter 1x TBS buffer 
 
 
9.11 Lysis buffer (1x RIPA) 
1 mL Tris-HCl, pH 7.5 (stock: 200 mM) 
1 mL NaCl (stock: 1.5 M) 
1 mL Na2EDTA (stock: 10 mM) 
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1 mL EGTA (stock: 10 mM) 
1 mL Igepal (stock: 10 %) 
1 mL Na-deoxycholate (stock: 10 %) 
1 mL Na-pyrophosphate (stock: 25 mM) 
1 mL β-glycerophosphate (stock: 10 mM) 
1 tab complete EDTA-free (for 10 mL) (Roche, (04693132001)) 
100 µL Inhibitor cocktail II (Sigma Aldrich, (P5726)) 
100 µL Inhibitor cocktail III (Sigma Aldrich, (P0044)) 
100 µL SDS (stock: 10 %) 
100 µL PMSF (stock: 1 M)  
H2O up to 10 mL 
 
9.12 BioRad 10x running buffer 
Dissolve 30 g Tris (250 mM), 144 g Glycine (2 mM) and 10 g SDS in 1 liter H2O 
pH adjustment is not required 
Working concentration: 1x  100 ml stock + 900 ml H2O 
 
9.13 10x transfer buffer + 20 % MeOH 
Dissolve 30 g Tris (250 mM), 144 g Glycine (2 mM) in 1 liter H2O 
pH adjustment is not required 
Working concentration: 1x  100 ml stock + 700 ml H2O + 200 ml Methanol 
 
9.14 5x SDS sample buffer (10 ml) 
0.6 ml 1 M Tris-HCl pH 6.8 (60 mM) 
5.0 ml 50 % Glycerol (25 %) 
2.0 ml 10 % SDS (2 %) 
0.5 ml β-Mercaptoethanol (14.4 mM) 
1.0 ml 1 % Bromophenolblue (0.1 %) 
0.9 ml ddH2O 
9.15 GST buffer 
50 mM Tris (pH 7.5) 
5 mM MgCl2 
200 mM NaCl 
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1 % Igepal 
5 % Glycerol 
 
9.16 10xTBS, 1 L, pH 7.5, PhosTag buffer 
100 mM Tris  
1 M NaCl 
Distilled water ad 0.9 l 
pH adjustment at 7.5 with HCl 
Distilled water for preparation of the 1 L solution 
 
9.17 1x TBS-T, PhosTag buffer 
Dissolve 1 ml Tween 20 in 1 liter 1x TBS buffer (PhosTag) 
 
9.18 2x HBS buffer 100 ml 
10  ml HEPES (0.5 M) pH 7.1 
9.3 ml NaCl (3 M) 
750 µl NaPO4 (0.1 M) pH 7.1 
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10 Abbreviations 
°C    degree Celsius 
aa    amino acid(s) 
A    acceptor fluorophore 
ddH2O   double distilled water 
D    donor fluorophore 
ET    energy transfer 
EtOH   ethanol 
eq    equivalent 
h    hour 
kDa    kilodalton 
min    minute 
μl    microliter 
M    mole 
mM    millimole 
µM    micromole 
nm    nanometer 
nM    nanomole 
RT    room temperature 
V    Volt 
 
 
Akt    Ser/Thr protein kinase  
(UniProt: Q9Y243) 
Arf    ADP-ribosylation factor (UniProt: P84077) 
Arl2    Arf-like protein 2 (UniProt: P36404) 
Arl3    Arf-like protein 3 (UniProt: P36405) 
APT    acyl protein thioesterase 
ATP    adenosine triphosphate 
2-BP    Bromopalmitate, palmitoylation inhibitor 
BSA    bovine serum albumin 
BTG2   protein for cell cycle control (UniProt: P78534) 
CA    cellular automaton 
CIAP   calf intestinal alkaline phosphatase 
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CML    chronic myeloid leukemia 
CNK   connector enhancer of kinase suppressor of 
Ras 1 
Cop-1   coat protein 1 (UniProt: P43254) 
CRC    colon rectal carcinoma 
Cy3.5   organic cyanine dye 
Cyclin D  cyclin protein family member, involved in cell 
cycle progression (UniProt: P30279) 
CypB   cyclophilin B (UniProt: Q3KQW3) 
DMEM   Dulbecco’s Modified Eagle Medium 
DMSO   dimethylsulfoxide 
DNA    deoxyribonucleic acid 
dsDNA   double-stranded DNA 
ssDNA   single-standed DNA 
dNTP   deoxyribonucleoside triphosphates 
Dox    doxycycline 
Dpn1   restriction enzyme which cuts methylated DNA 
DTT    dithiothreitol 
DUSP   dual specificity phosphatase 
4E-BP1   eukaryotic initiation factor 4E-binding protein 
EDTA   ethylenediaminetetraacetic acid 
EGF    Epidermal Growth Factor 
EGFR  Epidermal Growth Factor Receptor  
(UniProt: P00533) 
Elk-1  transcription activator protein (UniProt: 
P19419) 
ER    endoplasmic reticulum 
Erk2  extracellular-signal regulated kinase, MAPK, 
(UniProt: P28482) 
FACS   Fluorescence Activated Cell Sorting 
FCS    fetal calf serum 
FLAP   Fluorescence Loss After Photobleaching 
FLIM    Fluorescence Lifetime Imaging Microscopy 
FRET    Förster Resonance Energy Transfer 
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FTI    farnesyltransferase inhibitor 
Gab1   Grb2-associated-binding protein 1 
GAP    GTPase-activating protein 
GDP    Guanosine diphosphate 
GDI    GDP dissociation inhibitor 
GEF    guanine-nucleotide exchange factor 
GNBB   guanine nucleotide binding protein 
Grb2    growth factor receptor-bound protein 2 
GSH    glutathione 
GST    glutathion S-transferase 
GTP    guanosine-5'-triphosphate 
GTPase  hydrolase enzymes, binds and hydrolyzes 
GTP 
HVR  hypervariable region of Ras proteins 
Icmt  Protein-S-isoprenylcysteine O-
methyltransferase  (UniProt: O60725) 
JNK    c-Jun N-terminal kinase (UniProt: P53779) 
KC    mPDAC 79990, KRasG12D(-/+) 
KPC    mPDAC 79751, KRasG12D(-/+)p53R270H(-/+) 
KSR    kinase suppressor of Ras 1 
LB    lysogeny broth 
LSM    Laser-scanning microscopy 
LY294002   PI3K inhibitor 
MAPK  mitogen-activated protein kinase, Erk, MAP 
kinase 
MAPKK   Mek, MAP kinase kinase 
MAPKKK   Raf, MAP kinase kinase kinase 
mCitrine/mCit  monomeric variant of yellow fluorescent pro-
tein 
mCherry   monomeric variant of red fluorescent protein 
MDCK   Madin-Darby canine kidney cells 
MDM-2  Mouse double minute 2 homolog, E3 ubiquitin-
protein ligase (UniProt: Q00987) 
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Mek  dual specificity mitogen-activated protein ki-
nase kinase 1, MAPKK, (UniProt: Q02750) 
MeOH   methanol 
MNK    MAPK-interacting ser/thr kinase 
mTor  mammalian target of rapamycin (UniProt: 
P42345) 
Myc  regulator gene, encoding a transcription factor 
(UniProt: 01106) 
Net-1  neuroepithelial cell-transforming gene 1 pro-
tein (UniProt: Q7Z628) 
NSCLC    non-small cell lung cancer 
NTS    nuclear translocation signal 
p14/19 Arf  Arf tumor suppressor (UniProt: P42771), p19 
is the equivalent in mice 
p38 MAPK  mitogen-activated protein kinase (UniProt: 
Q16539) 
p53    tumor suppressor (UniProt: P04637) 
p53 RE   p53 responsive element 
p73  related to p53, involved in cell cycle (UniProt: 
O15350) 
pan Ras   all Ras isoforms 
PAT    palmitoyl transferase 
PBS    phosphate buffered saline 
PDAC   pancreatic ductal adenocarcinoma 
PDE    phosphodiesterase 
PDEδ   PDE6D (UniProt: O43924), subunit of PDE 
Pdx1   pancreatic progenitor cell gene promoter 
PFA    paraformaldehyde 
PI3K    phosphoinosite-3 kinase 
Pirh-2   ubiquitin-protein ligase 
PKC    protein kinase C 
PM     plasma membrane 
PT    PhosTag 
PTB    phosphotyrosine-binding domain 
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PTEN  phosphatases and tensin homolog (UniProt: 
P60484) 
PTM    post-translational modification 
PTP    protein tyrosine phosphatases 
PVDF   polyvinyliden difluoride 
Rab11   Ras-related protein Rab11A (UniProt: P62491) 
Rac  Ras-related C3 botulinum toxin substrate 1 
(UniProt: P63000) 
Raf  serine/threonine-protein kinase, MAPKKK 
(UniProt: P15056) 
Ras    small GTPase 
HRas   Harvey Ras (UniProt: P01112) 
NRas   neuroblastoma Ras (UniProt: P01111) 
KRas   Kirsten Ras (UniProt: P01116) 
RBD Ras-binding domain of Raf 
Rb retinoblastoma protein (UniProt: P06400) 
Rce1 Ras converting enzyme 1, CAAX prenyl pro-
tease 2, metalloproteinase (UniProt: Q9Y256) 
RE    recycling endosome 
RheB  Ras homolog enriched in brain (UniProt: 
Q15382) 
Rho  Ras homolog gene family member A, small 
GTPase (UniProt: P61586) 
RIPA   radioimmunoprecipitation assay buffer 
RNAi   RNA interference 
RPMI   Roswell Park Memorial Institute medium 
RSK    p90-ribosomal-S6-kinase 
RTCA   real-time cell analyzer 
RTK    receptor tyrosine kinase 
SDS    sodium dodecyl sulfate 
SEM    standard error of mean 
Ser    serine, S 
SH2    Src-homology-domain 2 
SH3    Src-homology-domain 3 
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shRNA   small hairpin RNA 
Siah-1  E3 ubiquitin-protein ligase 1 (UniProt: 
Q8IUQ4) 
siRNA   small interfering RNA 
SOS    son of sevenless (UniProt: Q07899) 
SRE    serum-response element 
SRF    serum-response factor 
TB    terrific broth 
TBS     Tris-buffered saline 
TCF    ternary complex factor 
TCSPC    time-correlated single photon counting  
TKi    tyrosine kinase inhibitor 
TSC1   Hamartin, Tuberous Sclerosis Complex 1 
TSC2   Tuberin, Tuberous Sclerosis Complex 2 
Wip-1   protein phosphatases 1D (UniProt: O15297) 
wt    wild-type 
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Figure 54: Representation of the 20 proteinogenic amino acids, including the full name and 3- and 
1-letter code for each structure. Figure adapted from www.neb.com (24.03.2015) 
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